Improved method for the formation of amides

The biocatalytic method employing mutated Sphingomonas Lipase enzyme variants for amide synthesis from esters and acids addresses the inefficiencies of traditional chemical routes by achieving high conversion rates and improved safety and sustainability in amide formation.

WO2024240748A1PCT designated stage expired Publication Date: 2024-11-28BASF SE
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/063926
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-21
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current methods for amide formation in pharmaceutical and agrochemical industries face challenges such as the use of toxic reagents, poor atom economy, sustainability issues, and inefficiencies with certain substrates, particularly with chemical routes that require hazardous catalysts and result in racemization and safety concerns.

Method used

A biocatalytic method using mutated Sphingomonas Lipase enzyme variants to catalyze amide synthesis from (hetero)aromatic esters and acids in both aqueous and organic solvents, avoiding harmful reagents and operating under mild conditions.

Benefits of technology

This method achieves high conversion rates of acyl donors to amides with improved safety, sustainability, and efficiency, particularly with challenging substrates like anilines and heterocycles, while minimizing racemization and environmental impact.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000046_0001
    Figure IMGF000046_0001
  • Figure IMGF000046_0002
    Figure IMGF000046_0002
  • Figure IMGF000051_0001
    Figure IMGF000051_0001
Patent Text Reader

Abstract

The present invention is in the field of biocatalysis, bio-conversion and fermentation and is directed to a method for the enzymatic production of amides from (aromatic) esters or acids.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]Improved method for the formation of amides Field of the Invention The present invention is in the field of biocatalysis, bio-conversion and fermentation and is directed to a method for the enzymatic synthesis of amides in water from mono- and bicyclic acyl donors preferably containing het- eroatoms at the beta- or gamma - position. Introduction Amide formation between an amine and a carboxylic acid is one of the most important re- actions in the syn- thesis of compounds applied in the pharmaceutical or agrochemical industries. The synthetic approaches to obtain am- ides appear simple, but are disadvantageous due to the requirement of toxic or hazardous reagents for the activation of the acid component or have poor atom economy. So far, many strategies to obtain amides have been published, but still several problems have not been solved yet. For example, chemical routes (chlorin- ating agents, acid chloride, coupling reagents, mixed anhydride) require coupling agents such as 1-Ethyl-3- (3-dimethylaminopropyl)carbodiimide-hydrochlorid (EDC-HCl), dicyclohexylcarbodiimide (DCC), O-(7- Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium-hexafluorphosphat (HATU), 2-(1H-Benzotriazol-1-yl)- 1,1,3,3-tetramethyluronium-hexafluorophosphat (HBTU), propylphosphonic anhydride (T3P), thionylchloride (SOCl2), cobalt chloride (CoCl2) in organic solvents (e.g. DMF, DMA, DCM, THF, MeCN) to activate carbox- ylic acids for amide formation. Consequently, these reactions have a poor atom economy and struggle with sustainability and safety issues. Furthermore, chemical routes using boron-based catalyst bear the risk of potential reproductive toxicity of boric acid and lack of catalyst activity with more challenging substrates such as anilines, heterocyclics and amino acids. In addition, chemical routes using B-N-B heterocyclic cata- lysts have the disadvantage that less nucleophilic amines do not work well, and can probably not be scaled efficiently, while the synthetic effort required to prepare the catalyst is very high. Chemical routes using group(IV) metal catalyst are not suitable for efficient large scale application and little is known about its reac- tivity with heterocycles or anilines. Further challenges are for example the direct transformation of carboxylic acid with an amine or the transformation of esters to amides. Known chemical strategies for this reaction with esters and carboxylic acid require activation of the substrate like SOCl2, leading to a reactive acyl chloride which reacts subsequently with amine to yield the amide. This reaction suffers from poor atom economy, de- manding safety concepts at large scale and racemization of the alpha centre in the acid. In view of the prior art, the problem of the present invention, thus, relates to the provision of an alternative method for amide formation which avoids the disadvantages of the methods known in the art described SU- PRA, by using harmless reagents and working under mild conditions. To solve this problem, the inventors of the present invention have developed a biocatalytic method for amide formation, especially by employing cer- tain hydrolases, starting from (hetero)aromatic esters and acids. Furthermore, the inventors have generated new mutated Sphingomonas Lipase enzyme variants which are capable of catalyzing the synthesis of amides using said esters and acids in both aqueous and organic solvents. Description of the drawing Figure 1: Formation of the corresponding acid from ethyl picolinate with benzylamine at different pHs using SpLWt. Reaction consisted of 10 mM ester, 20 mM amine, 200 mM of buffer, and 0.2 mg / mL CFE. Samples were taken after 10 min. Figure 2: Formation of the corresponding amide from ethyl picolinate in the presence of benzylamine at different pHs using SpLWt. Reaction consisted of 10 mM ester, 20 mM amine, 200 mM of buffer, and 0.2 mg / mL CFE. Sam- ples were taken after 10 min. Figure 3: Formation of the corresponding acid from ethyl 2-furoate in the presence of benzylamine at different pHs using SpLWt. Reaction consisted of 10 mM ester, 20 mM amine, 200 mM of buffer, and 0.5 mg / mL CFE. Samples were taken after 10 min. Figure 4: Formation of the corresponding amide from ethyl 2-furoate in the presence of benzylamine at different pHs using SpLWt. Reaction consisted of 10 mM ester, 20 mM amine, 200 mM of buffer, and 0.5 mg / mL CFE. Sam- ples were taken after 10 min Figure 5: Formation of the corresponding acid and amide from ethyl picolinate in the presence of benzylamine at different pHs using SpLWt. The acid values here were not substracted from reactions w / o SpLWt. Reaction con- sisted of 10 mM ester, 20 mM amine, 200 mM of buffer, and 0.2 mg / mL CFE. Samples were taken after 10 min Figure 6: Formation of the corresponding acid and amide from ethyl 2-furoate in the presence of benzylamine at different pHs using SpLWt. The acid values here were not substracted from reactions w / o SpLWt. Reaction consisted of 10 mM ester, 20 mM amine, 200 mM of buffer, and 0.5 mg / mL CFE. Samples were taken after 10 min. Figure 7: Comparison of the SpLD158 variants in regards of amide and acid formation. The reaction contained lyophilized CFE (0.2 mg / mL), ester (10 mM), amine (20 mM) in 200 mM KPi buffer (pH 7.5) and was incubated at30◦C for 10 min.Figure 8: Results for SpLD158N after 1, 2, and 4 h. The reaction mixture was not changed as compared to Fig- ure 7. Legend to the sequence listing SEQ ID DNA SEQ-IDproteinorganism of wt sequence1 2 Sphingomonas sp. 3 4 Sphingomonas sp. 5 6 Sphingomonas sp. 7 8 Sphingomonas sp. 9 10 Sphingomonas sp. 11 12 Sphingomonas sp. 13 14 Sphingomonas sp. 15 16 Sphingomonas sp. 17 18 Sphingomonas sp. 19 20 Sphingomonas sp. 21 22 Sphingomonas sp. 23 24 Sphingomonas sp. 26 Sphingomonas sp.28Pseudomonas aestusnigri VGXO14 Halop-seudomonas aestusnigri (UniProt) 30 Pseudomonas aestusnigri VGXO14 32 Alcanivorax borkumensis SK2 34 Alcanivorax borkumensis SK2 36 Bradyrhizobium japonicum 38 Pseudomonas putida 40 Rhodococcus globerulus 42 Pseudomonas protegens (DSM19095) 44 Bacillus subtilis 46 Candida antarctica 48 Candida antarctica 50 Candida antarctica 52 Candida antarctica 54 Candida antarctica 56 Candida antarctica 58 unknown 60 unknown 62 Rhizomucor miehei 64 Serratia marcescens 66 Nocardia farcinica 68 Rhodospirillaceae bacterium 70 Microbacterium azadirachtae 72 Rhodococcus sp. Oct1 74 Actinomycetospora cinnamomea 76 Pseudonocardia dioxanivorans 78 Blastococcus sp. DSM 46786 80 Microbacterium sp. MYb64 82 Mesorhizobium australicum 84 Rhodococcus maanshanensis 86 Streptomyces cinnamoneus 88 Micobacterium smegmatis 90 Micobacterium smegmatis 92 Micobacterium smegmatis 94 Micobacterium smegmatis 96 Micobacterium smegmatis 98 Micobacterium smegmatis 100 Micobacterium smegmatis 102 Micobacterium smegmatis 104 Micobacterium smegmatis 106 Micobacterium smegmatis 107 108 Micobacterium smegmatis 109 110 Micobacterium smegmatis 111 112 Micobacterium smegmatis 113 114 Micobacterium smegmatis 115 116 Micobacterium smegmatis 117 118 Micobacterium smegmatis 119 120 Micobacterium smegmatis 121 Pseudomonas protegens PhlA 122 Pseudomonas protegens PhlB 123 124 Pyrobaculum calidifontis 125 126 Alyciclobacillus acidocaldarius Detailed description of the Invention A first embodiment of the invention comprises an isolated hydrolase capable of catalyzing the reaction from an acyl donor to an amide in an aqueous medium comprising, a hydrolase, an amine, an acyl donor, and optionally a solvent, wherein after incubation at least 10%, preferably at least 15%, more preferably at least 20%, even more preferably at least 25%, even more preferably at least 30%, even more preferably at least 35%, even more preferably at least 40%, even more preferably at least 45%, even more preferably at least 50%, even more preferably at least 50%, even more preferably at least 55%, even more preferably at least 60%, even more preferably at least 65%, even more preferably at least 70%, even more preferably at least 75%, even more preferably at least 80%, even more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, even more preferably at least 96%, 97%, 98%, 99% or 100% of the acyl donor have been converted to an amide. The solvent as used herein is meant to include both organic systems with water as well as aqueous systems with organic co-solvents. An “acyl donor” as used herein is meant to include esters, amides, thioesters and carboxylic acids. The incubation time of the aqueous medium may be at least 5min, at least 10min, at least 0,5h, at least 1h, at least 1,5h, at least 2h, at least 2,5h, at least 5h, at least 10h at least 12h, or at least 24h. In one embodiment the incubation is performed a temperature from 5°C to 80°C, preferably, at 10°C to 50°C, preferably at 15°C to 40°C, more preferably at 20°C to 40°C, even more preferably at 24°C to 37°C, most prefer- ably at 28°C to 32°C. In a preferred embodiment after incubation for 10 hours at 30°C at least 20% of the acyl donor have been con- verted to an amide. In a more preferred embodiment after incubation for 7 hours at 30°C at least 20% of the acyl donor have been converted to an amide. In an even more preferred embodiment after incubation for 7 hours at 30°C at least 25% of the acyl donor have been converted to an amide. In an even more preferred em- bodiment after incubation for 18h at 30°C at least 40% of the acyl donor have been converted to an amide. In a most preferred embodiment after incubation for up to 5 hours at 30°C at least 25% of the acyl donor have been converted to an amide. In a further preferred embodiment, the acyl donor contains heteroatoms at the beta- or gamma - position in wa- ter. The “hydrolase” as used herein includes enzymes such as lipases, phosphatases, glycosidases, peptidases, and nucleosidases. Particularly useful are acid hydrolases which include nucleases, proteases, glycosidases, lipases, phosphatases, sulfatases, and phospholipases. In a particularly preferred embodiment, the hydrolase is a serine hydrolase which possesses a nucleophilic serine in the active site, which is used for substrate hydroly- sis. The inventors of the present invention have surprisingly found out that the aspartic acid residue next to said serine of a serine hydrolase. i.e the initial acyl donor is rather converted into an amide than being hydrolyzed. In one embodiment, the isolated hydrolase is comprising a sequence selected from the group consisting of a. The amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124 or 126, and b. An amino acid molecule having at least 50% identity to the amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 or a functional fragment thereof, and c. An amino acid molecule encoded by a nucleic acid molecule of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125, or a functional fragment thereof, and d. An amino acid molecule encoded by a nucleic acid molecule having at least 50% identity to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125, or a functional fragment thereof, and e. An amino acid molecule encoded by a nucleic acid molecule hybridizing under stringent conditions to a fragment of at least 250 bases complementary to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125, or a functional frag- ment thereof, wherein the amino acid molecule as defined in b., c., d. and e. is catalysing the reaction from an acyl donor to an amide in an aqueous medium, and, wherein after incubation at least 10%, preferably at least 15%, more preferably at least 20%, even more prefera- bly at least 25%, even more preferably at least 30%, even more preferably at least 35%, even more preferably at least 40%, even more preferably at least 45%, even more preferably at least 50%, even more preferably at least 55%, even more preferably at least 60%, even more preferably at least 65%, even more preferably at least 70%, even more preferably at least 75%, even more preferably at least 80%, even more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, even more preferably at least 96%, 97%, 98%, 99% or 100% of the acyl donor have been converted to an amide. In a particularly preferred embodiment, the amino acid corresponding to position 158, and / or 159 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 158 of SEQ ID NO: 2 is substituted by Glu, Ser, His, Tyr, Asn, Arg, Lys, Gln, or Tyr. In another preferred embodiment, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by Asn, Ser, Tyr, or Val. The incubation time of the aqueous medium may be at least 5min, at least 10min, at least 0,5h, at least 1h, at least 1,5h, at least 2h, at least 2,5h, at least 5h, at least 10h at least 12h, or at least 24h. In one embodiment the incubation is performed at a temperature between 5°C and 80°C, preferably 10°C to 50°C, preferably at 15°C to 40°C, more preferably at 20°C to 40°C, even more preferably at 24°C to 37°C, most preferably at 28°C to 32°C. In a preferred embodiment after incubation for 10 hours at 30°C at least 20% of the acyl donor have been con- verted to an amide. In a more preferred embodiment after incubation for 7 hours at 30°C at least 20% of the acyl donor have been converted to an amide. In an even more preferred embodiment after incubation for 7 hours at 30°C at least 25% of the acyl donor have been converted to an amide. In an even more preferred em- bodiment after incubation for 18h at 30°C at least 40% of the acyl donor have been converted to an amide. In a most preferred embodiment after incubation for up to 5 hours at 30°C at least 25% of the acyl donor have been converted to an amide. A further embodiment of the invention is an isolated hydrolase comprising a sequence selected from the group consisting of a. The amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 and b. An amino acid molecule having at least 50% identity to the amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 or a functional fragment thereof, and c. An amino acid molecule encoded by a nucleic acid molecule of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and d. An amino acid molecule encoded by a nucleic acid molecule having at least 50% identity to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and e. An amino acid molecule encoded by a nucleic acid molecule hybridizing under stringent conditions to a fragment of at least 250 bases complementary to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional frag- ment thereof, wherein the amino acid molecule as defined in b., c., d. and e. is catalysing the reaction from an acyl donor to an amide in an aqueous medium. In a particularly preferred embodiment, the amino acid corresponding to position 158, and / or 159 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 158 of SEQ ID NO: 2 is substituted by Glu, Ser, His, Tyr, Asn, Arg, Lys, Gln, or Tyr. In another preferred embodiment, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by Asn, Ser, Tyr, or Val. A further embodiment of the invention is a process for producing an amide comprising the steps of i. Providing an aqueous medium comprising a hydrolase, an amine, an acyl donor, and optionally a solvent, and ii. Incubating the aqueous medium and iii. Optionally isolating the amide from the reaction mixture, wherein the one or more hydrolase is capable of catalysing the reaction from an acyl donor to an amide in an aqueous medium comprising a hydrolase, an amine, an acyl donor, and optionally a solvent , wherein after incu- bation at least 10%, preferably at least 15%, more preferably at least 20%, even more preferably at least 25%, even more preferably at least 30%, even more preferably at least 35%, even more preferably at least 40%, even more preferably at least 45%, even more preferably at least 50%, even more preferably at least 55%, even more preferably at least 60%, even more preferably at least 65%, even more preferably at least 70%, even more preferably at least 75%, even more preferably at least 80%, even more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, even more preferably at least 96%, 97%, 98%, 99% or 100% of the acyl donor have been converted to an amide. The incubation time of the aqueous medium may be at least 5min, at least 10min, at least 0,5h, at least 1h, at least 1,5h, at least 2h, at least 2,5h, at least 5h, at least 10h at least 12h, or at least 24h. In one embodiment the incubation is performed at a temperature from 5°C to 80°C, preferably at 10°C to 50°C, preferably at 15°C to 40°C, more preferably at 20°C to 40°C, even more preferably at 24°C to 37°C, most pref- erably at 28°C to 32°C. In a preferred embodiment after incubation for 10 hours at 30°C at least 20% of the acyl donor have been con- verted to an amide. In a more preferred embodiment after incubation for 7 hours at 30°C at least 20% of the acyl donor have been converted to an amide. In an even more preferred embodiment after incubation for 7 hours at 30°C at least 25% of the acyl donor have been converted to an amide. In an even more preferred em- bodiment after incubation for 18h at 30°C at least 40% of the acyl donor have been converted to an amide. In a most preferred embodiment after incubation for up to 5 hours at 30°C at least 25% of the acyl donor have been converted to an amide. The aqueous medium may be a solution or a suspension or a solution and a suspension, wherein any of the substances comprised in said aqueous medium may be fully or partially dissolved and / or partially or fully sus- pended. In one embodiment of the process of the invention the hydrolase is comprising a sequence selected from the group consisting of a. The amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 and b. An amino acid molecule having at least 50% identity to the amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 or a functional fragment thereof, and c. An amino acid molecule encoded by a nucleic acid molecule of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and d. An amino acid molecule encoded by a nucleic acid molecule having at least 50% identity to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and e. An amino acid molecule encoded by a nucleic acid molecule hybridizing under stringent conditions to a fragment of at least 250 bases complementary to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional frag- ment thereof, wherein the amino acid molecule as defined in b., c., d. and e. is catalysing the reaction from an acyl donor to an amide in an aqueous medium and wherein after incubation at least 10%, preferably at least 15%, more pref- erably at least 20%, even more preferably at least 25%, even more preferably at least 30%, even more prefera- bly at least 35%, even more preferably at least 40%, even more preferably at least 45%, even more preferably at least 50%, even more preferably at least 55%, even more preferably at least 60%, even more preferably at least 65%, even more preferably at least 70%, even more preferably at least 75%, even more preferably at least 80%, even more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, even more preferably at least 96%, 97%, 98%, 99% or 100% of the acyl donor have been converted to an amide. In a particularly preferred embodiment, the amino acid corresponding to position 158, and / or 159 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 158 of SEQ ID NO: 2 is substituted by Glu, Ser, His, Tyr, Asn, Arg, Lys, Gln, or Tyr. In another preferred embodiment, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by Asn, Ser, Tyr, or Val. The incubation time of the aqueous medium may be at least 5min, at least 10min, at least 0,5h, at least 1h, at least 1,5h, at least 2h, at least 2,5h, at least 5h, at least 10h at least 12h, or at least 24h. In one embodiment the incubation is performed at 5°C to 80°C, 10°C to 50°C, preferably at 15°C to 40°C, more preferably at 20°C to 40°C, even more preferably at 24°C to 37°C, most preferably at 28°C to 32°C. In a preferred embodiment after incubation for 10 hours at 30°C at least 20% of the acyl donor have been con- verted to an amide. In a more preferred embodiment after incubation for 7 hours at 30°C at least 20% of the acyl donor have been converted to an amide. In an even more preferred embodiment after incubation for 7 hours at 30°C at least 25% of the acyl donor have been converted to an amide. In an even more preferred em- bodiment after incubation for 18h at 30°C at least 40% of the acyl donor have been converted to an amide. In a most preferred embodiment after incubation for up to 5 hours at 30°C at least 25% of the acyl donor have been converted to an amide. A further embodiment of the invention is a process for producing an amide comprising the steps of i. Providing an aqueous medium comprising a hydrolase, an amine, an acyl donor, and optionally a solvent, and, ii. Incubating the aqueous medium and iii. Optionally isolating the amide from the reaction mixture, wherein the one or more hydrolase is comprising a sequence selected from the group consisting of a. The amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 and b. An amino acid molecule having at least 50% identity to the amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 or a functional fragment thereof, and c. An amino acid molecule encoded by a nucleic acid molecule of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and d. An amino acid molecule encoded by a nucleic acid molecule having at least 50% identity to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and e. An amino acid molecule encoded by a nucleic acid molecule hybridizing under stringent conditions to a fragment of at least 250 bases complementary to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional frag- ment thereof, wherein the amino acid molecule as defined in b., c., d. and e. is catalysing the reaction from an acyl do- nor to an amide in an aqueous medium. The aqueous medium may be a solution or a suspension or emulsion / dispersion, wherein any of the substances comprised in said aqueous medium may be fully or partially dissolved and / or partially or fully suspended. A further embodiment of the invention is a recombinant construct comprising a nucleic acid molecule encoding a hydrolase wherein the hydrolase is comprising a sequence encoding an amino acid molecule selected from the group consisting of a. The amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 and b. An amino acid molecule having at least 50% identity to the amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 or a functional fragment thereof, and c. An amino acid molecule encoded by a nucleic acid molecule of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and d. An amino acid molecule encoded by a nucleic acid molecule having at least 50% identity to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and e. An amino acid molecule encoded by a nucleic acid molecule hybridizing under stringent conditions to a fragment of at least 250 bases complementary to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional frag- ment thereof, wherein the amino acid molecule as defined in b., c., d. and e. is catalysing the reaction from an acyl donor to an amide in an aqueous medium. In a particularly preferred embodiment, the amino acid corresponding to position 158, and / or 159 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 158 of SEQ ID NO: 2 is substituted by Glu, Ser, His, Tyr, Asn, Arg, Lys, Gln, or Tyr. In another preferred embodiment, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by Asn, Ser, Tyr, or Val. Said recombinant construct for expressing the nucleic acid encoding a hydrolase may be integrated into the ge- nome of an organism or the recombinant construct for expressing the nucleic acid encoding a hydrolase may be comprised on a vector such as a plasmid or viral vector that is introduced into an organism. The nucleic acid encoding a hydrolase in the recombinant construct may be functionally linked to a heterologous promoter, a heterologous terminator and / or any other heterologous genetic element. A further embodiment of the invention is a recombinant vector, such a s an expression vector or a viral vector comprising said recombinant construct. A further embodiment of the invention is a recombinant microorganism comprising said recombinant construct or said recombinant vector. In some embodiments, the recombinant microorganism is a prokaryotic cell. Suitable prokaryotic cells include Gram-positive, Gram negative and Gram-variable bacterial cells, preferably Gram-negative. Thus, prokaryotic microorganisms that can be used in the present invention include, but are not limited to, Glu- conobacter oxydans, Gluconobacter asaii, Achromobacter delmarvae, Achromobacter viscosus, Achromobacter lacticum, Agrobacterium tumefaciens, Agrobacterium radiobacter, Alcaligenes faecalis, Arthrobacter citreus, Ar- throbacter tumescens, Arthrobacter paraffineus, Arthrobacter hydrocarboglutamicus, Arthrobacter oxydans, Au- reobacterium saperdae, Azotobacter indicus, Brevibacterium ammoniagenes, Brevibacterium divaricatum, Brevibacterium lactofermentum, Brevibacterium flavum, Brevibacterium globosum, Brevibacterium fuscum, Brevibacterium ketoglutamicum, Brevibacterium helcolum, Brevibacterium pusillum, Brevibacterium testaceum, Brevibacterium roseum, Brevibacterium immariophilium, Brevibacterium linens, Brevibacterium protopharmiae, Corynebacterium acetophilum, Corynebacterium glutamicum, Corynebacterium callunae, Corynebacterium acetoacidophilum, Corynebacterium acetoglutamicum, Enterobacter aerogenes, Erwinia amylovora, Erwinia ca- rotovora, Erwinia herbicola, Erwinia chrysanthemi, Flavobacterium peregrinum, Flavobacterium fucatum, Flavo- bacterium aurantinum, Flavobacterium rhenanum, Flavobacterium sewanense, Flavobacterium breve, Flavo- bacterium meningosepticum, Micrococcus sp. CCM825, Morganella morganii, Nocardia opaca, Nocardia ru- gosa, Planococcus eucinatus, Proteus rettgeri, Propionibacterium shermanii, Pseudomonas synxantha, Pseu- domonas azotoformans, Pseudomonas jluorescens, Pseudomonas ovalis, Pseudomonas stutzeri, Pseudomo- nas acidovolans, Pseudomonas mucidolens, Pseudomonas testosteroni, Pseudomonas aeruginosa, Rhodococ- cus erythropolis, Rhodococcus rhodochrous, Rhodococcus sp. ATCC 15592, Rhodococcus sp. ATCC 19070, Sporosarcina ureae, Staphylococcus aureus, Vibrio metschnikovii, Vibrio tyrogenes, Actinomadura madurae, Actinomyces violaceochromogenes, Kitasatosporia parulosa, Streptomyces avermitilis, Streptomyces coelicolor, Streptomyces flavelus, Streptomyces griseolus, Streptomyces lividans, Streptomyces olivaceus, Streptomyces tanashiensis, Streptomyces virginiae, Streptomyces antibioticus, Streptomyces cacaoi, Streptomyces lavendu- lae, Streptomyces viridochromogenes, Aeromonas salmonicida, Bacillus pumilus, Bacillus circulans, Bacillus thiaminolyticus, Escherichia freundii, Microbacterium ammoniaphilum, Serratia marcescens, Salmonella typhi- murium, Salmonella schottmulleri, Xanthomonas citri, Synechocystis sp., Synechococcus elongatus, Ther- mosynechococcus elongatus, Microcystis aeruginosa, Nostoc sp., N. commune, N.sphaericum, Nostoc puncti- forme , Spirulina platensis, Lyngbya majuscula, L. lagerheimii, Phormidium tenue, Anabaena sp., Lep- tolyngbya sp. Eukaryotic microorganisms that can be used in the present invention include, but are not limited to Ashbya gossypii, Saccharomyces spec, such as Saccharomyces cerevisiae, Hansenula spec, such as Hansenula poly- morpha, Schizosaccharomyces spec, such as Schizosaccharomyces pombe, Kluyveromyces spec, such as Kluyveromyces lactis and Kluyveromyces marxianus, Yarrowia spec, such as Yarrowia lipolytica, Pichia spec, such as Pichia methanolica, Pichia stipites and Pichia pastoris, Zygosaccharomyces spec, such as Zygosac- charomyces rouxii and Zygosaccharomyces bailii, Candida spec, such as Candida boidinii, Candida utilis, Can- dida freyschussii, Candida glabrata and Candida sonorensis, Schwanniomyces spec, such as Schwanniomyces occidentalis, Arxula spec, such as Arxula adeninivorans, Ogataea spec such as Ogataea minuta, Klebsiella spec, such as Klebsiella pneumonia, Aspergillus spec. such as Aspergillus niger or Myceliophthora thermophila. Preferred microorganisms of the invention comprise Rhodococcus rhodochrous, Aerococcus sp., Aspergillus sp., Ashyba gossypii, Bacillus pumilus, Bacillus subtilis, Bacteroides thetaiotaomicron, Clostridium algidicarnis, Corynebacterium efficiens, Corynebacterium glutamicum, Escherichia coli, Haloferax volcanii, Lactobacillus ca- sei, Methanocaldococcus jannaschii, Methanothermobacter thermautotrophicus, Myceliophthora thermophila, Pichia pastoris, Pseudomonas synxantha, Pseudomonas azotoformans, Pseudomonas jluorescens, Pseudomo- nas ovalis, Pseudomonas stutzeri, Pseudomonas acidovolans, Pseudomonas mucidolens, Pseudomonas tes- tosteroni, Pseudomonas aeruginosa, Pseudozyma tsukubaensis, Ralstonia eutropha, Rhodobacter sphaeroides, Rhodococcus opacus, Saccharomyces cerevisiae, Shigella boydii, Sinorhizobium meliloti, Strepto- myces antibioticus, Streptomyces avermitilis, Streptomyces cacaoi, Streptomyces coelicolor, Streptomyces fla- velus, Streptomyces griseolus, Streptomyces lavendulae, Streptomyces lividans, Streptomyces olivaceus, Streptomyces tanashiensis, Streptomyces virginiae, Streptomyces viridochromogenes, Thermoplasma acidophi- lum, Vibrio natrigens or Yarrowia lipolytica. Especially preferred microorganisms are Bacillus subtilis, Corynebacterium glutamicum, Escherichia coli, Pseu- domonas aeruginosa, Pseudomonas putida, Rhodobacter sphaeroides, Rhodococcus opacus, Saccharomyces cerevisiae, Ashbya gossypii, and Yarrowia lipolytica. A further embodiment of the invention is a composition comprising a hydrolase, an amine, an acyl donor, and optionally a solvent, wherein the hydrolase is comprising a sequence selected from the group consisting of a. The amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 and b. An amino acid molecule having at least 50% identity to the amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 or a functional fragment thereof, and c. An amino acid molecule encoded by a nucleic acid molecule of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and d. An amino acid molecule encoded by a nucleic acid molecule having at least 50% identity to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and e. An amino acid molecule encoded by a nucleic acid molecule hybridizing under stringent conditions to a fragment of at least 250 bases complementary to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional frag- ment thereof, wherein the amino acid molecule as defined in b., c., d. and e. is catalysing the reaction from an acyl donor to an amide in an aqueous medium. In a particularly preferred embodiment, the amino acid corresponding to position 158, and / or 159 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 158 of SEQ ID NO: 2 is substituted by Glu, Ser, His, Tyr, Asn, Arg, Lys, Gln, or Tyr. In another preferred embodiment, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by Asn, Ser, Tyr, or Val. Another embodiment of the invention is a recombinant microorganism comprising an introduced, increased or enhanced activity and / or expression of one or more hydrolase, wherein the one or more hydrolase is capable of catalysing the reaction from an acyl donor or carboxylic acid to an amide, and wherein the hydrolase is comprising a sequence selected from the group consisting of a. The amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 and b. An amino acid molecule having at least 50% identity to the amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, or 122, 124, or 126 or a functional fragment thereof, and c. An amino acid molecule encoded by a nucleic acid molecule of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and d. An amino acid molecule encoded by a nucleic acid molecule having at least 50% identity to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and e. An amino acid molecule encoded by a nucleic acid molecule hybridizing under stringent conditions to a fragment of at least 250 bases complementary to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional frag- ment thereof, and wherein the amino acid molecule as defined in b., c., d. and e. is catalysing the reaction from an acyl donor to an amide. In a particularly preferred embodiment, the amino acid corresponding to position 158, and / or 159 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 158 of SEQ ID NO: 2 is substituted by Glu, Ser, His, Tyr, Asn, Arg, Lys, Gln, or Tyr. In another preferred embodiment, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by Asn, Ser, Tyr, or Val. Another embodiment of the invention is a method for fermentative production of an amide comprising the steps of i. Providing a recombinant microorganism comprising an introduced, increased or enhanced activity and / or expression of one or more hydrolase, ii. Culturing said microorganism in a medium comprising an acyl donor or carboxylic acid, an amine under conditions that allow for the production of an amide and optionally isolating said an amide from the medium. A further embodiment of the invention is a composition comprising one or more recombinant microorganisms comprising an introduced, increased or enhanced activity and / or expression of one or more hydrolase. In one embodiment, said composition is further comprising an acyl donor, an amine, a medium and a carbon source. A further embodiment of the invention is a method for producing a recombinant microorganism comprising an introduced, increased or enhanced activity and / or expression of one or more hydrolase, said method compris- ing: (I) introducing, increasing or enhancing the activity and / or expression of a hydrolase gene encoding a hy- drolase enzyme having a hydrolyzing activity in said microorganism The recombinant microorganism produced according to the method as defined above or used in the method for fermentative production of an amide is preferably selected from the list comprising Ashbya gossypii, Glucono- bacter oxydans, Gluconobacter asaii, Achromobacter delmarvae, Achromobacter viscosus, Achromobacter lacticum, Agrobacterium tumefaciens, Agrobacterium radiobacter, Alcaligenes faecalis, Arthrobacter citreus, Ar- throbacter tumescens, Arthrobacter paraffineus, Arthrobacter hydrocarboglutamicus, Arthrobacter oxydans, Au- reobacterium saperdae, Azotobacter indicus, Brevibacterium ammoniagenes, Brevibacterium divaricatum, Brevibacterium lactofermentum, Brevibacterium flavum, Brevibacterium globosum, Brevibacterium fuscum, Brevibacterium ketoglutamicum, Brevibacterium helcolum, Brevibacterium pusillum, Brevibacterium testaceum, Brevibacterium roseum, Brevibacterium immariophilium, Brevibacterium linens, Brevibacterium protopharmiae, Corynebacterium acetophilum, Corynebacterium glutamicum, Corynebacterium callunae, Corynebacterium acetoacidophilum, Corynebacterium acetoglutamicum, Enterobacter aerogenes, Erwinia amylovora, Erwinia ca- rotovora, Erwinia herbicola, Erwinia chrysanthemi, Flavobacterium peregrinum, Flavobacterium fucatum, Flavo- bacterium aurantinum, Flavobacterium rhenanum, Flavobacterium sewanense, Flavobacterium breve, Flavo- bacterium meningosepticum, Micrococcus sp. CCM825, Morganella morganii, Nocardia opaca, Nocardia ru- gosa, Planococcus eucinatus, Proteus rettgeri, Propionibacterium shermanii, Pseudomonas synxantha, Pseu- domonas azotoformans, Pseudomonas jluorescens, Pseudomonas ovalis, Pseudomonas stutzeri, Pseudomo- nas acidovolans, Pseudomonas mucidolens, Pseudomonas testosteroni, Pseudomonas aeruginosa, Rhodococ- cus erythropolis, Rhodococcus rhodochrous, Rhodococcus sp. ATCC 15592, Rhodococcus sp. ATCC 19070, Sporosarcina ureae, Staphylococcus aureus, Vibrio metschnikovii, Vibrio tyrogenes, Actinomadura madurae, Actinomyces violaceochromogenes, Kitasatosporia parulosa, Streptomyces avermitilis, Streptomyces coelicolor, Streptomyces flavelus, Streptomyces griseolus, Streptomyces lividans, Streptomyces olivaceus, Streptomyces tanashiensis, Streptomyces virginiae, Streptomyces antibioticus, Streptomyces cacaoi, Streptomyces lavendu- lae, Streptomyces viridochromogenes, Aeromonas salmonicida, Bacillus pumilus, Bacillus circulans, Bacillus thiaminolyticus, Escherichia freundii, Microbacterium ammoniaphilum, Serratia marcescens, Salmonella typhi- murium, Salmonella schottmulleri, Xanthomonas citri, Synechocystis sp., Synechococcus elongatus, Ther- mosynechococcus elongatus, Microcystis aeruginosa, Nostoc sp., N. commune, N.sphaericum, Nostoc puncti- forme, Spirulina platensis, Lyngbya majuscula, L. lagerheimii, Phormidium tenue, Anabaena sp., Leptolyngbya sp., Saccharomyces spec, such as Saccharomyces cerevisiae, Hansenula spec, such as Han- senula polymorpha, Schizosaccharomyces spec, such as Schizosaccharomyces pombe, Kluyveromyces spec, such as Kluyveromyces lactis and Kluyveromyces marxianus, Yarrowia spec, such as Yarrowia lipolytica, Pichia spec, such as Pichia methanolica, Pichia stipites and Pichia pastoris, Zygosaccharomyces spec, such as Zygo- saccharomyces rouxii and Zygosaccharomyces bailii, Candida spec, such as Candida boidinii, Candida utilis, Candida freyschussii, Candida glabrata and Candida sonorensis, Schwanniomyces spec, such as Schwannio- myces occidentalis, Arxula spec, such as Arxula adeninivorans, Ogataea spec such as Ogataea minuta, Klebsiella spec, such as Klebsiella pneumonia, Aspergillus spec. such as Aspergillus niger or Myceliophthora thermophila. More preferably the recombinant microorganism is Rhodococcus rhodochrous, Aerococcus sp., Aspergillus sp., Bacillus pumilus, Bacillus subtilis, Bacteroides thetaiotaomicron, Clostridium algidicarnis, Corynebacterium effi- ciens, Corynebacterium glutamicum, Escherichia coli, Haloferax volcanii, Lactobacillus casei, Methanocaldococ- cus jannaschii, Methanothermobacter thermautotrophicus, Myceliophthora thermophila, Pichia pastoris, Pseu- domonas synxantha, Pseudomonas azotoformans, Pseudomonas jluorescens, Pseudomonas ovalis, Pseudo- monas stutzeri, Pseudomonas acidovolans, Pseudomonas mucidolens, Pseudomonas testosteroni, Pseudomo- nas aeruginosa, Pseudozyma tsukubaensis, Ralstonia eutropha, Rhodobacter sphaeroides, Rhodococcus opa- cus, Saccharomyces cerevisiae, Shigella boydii, Sinorhizobium meliloti, Streptomyces antibioticus, Streptomy- ces avermitilis, Streptomyces cacaoi, Streptomyces coelicolor, Streptomyces flavelus, Streptomyces griseolus, Streptomyces lavendulae, Streptomyces lividans, Streptomyces olivaceus, Streptomyces tanashiensis, Strepto- myces virginiae, Streptomyces viridochromogenes, Thermoplasma acidophilum, Vibrio natrigens or Yarrowia lipolytica. Especially preferred recombinant microorganisms are Bacillus subtilis, Corynebacterium glutamicum, Esche- richia coli, Pseudomonas aeruginosa, Pseudomonas putida, Rhodobacter sphaeroides, Rhodococcus opacus, Saccharomyces cerevisiae, Pichia pastoris, Aspergillus sp., and Yarrowia lipolytica. A further embodiment of the invention is a recombinant expression construct comprising i. a promoter functional in a microorganism functionally linked to a nucleic acid molecule encoding a hydro- lase wherein at least one of the promoters functionally linked to the nucleic acid molecule encoding the hydrolase is heterologous to the nucleic acid molecule encoding the hydrolase, wherein the hydrolase is comprising a sequence encoding an amino acid molecule selected from the group con- sisting of a. The amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 and b. An amino acid molecule having at least 50% identity to the amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 or a functional fragment thereof, and c. An amino acid molecule encoded by a nucleic acid molecule of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and d. An amino acid molecule encoded by a nucleic acid molecule having at least 50% identity to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and e. An amino acid molecule encoded by a nucleic acid molecule hybridizing under stringent conditions to a fragment of at least 250 bases complementary to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional frag- ment thereof, and wherein the amino acid molecule as defined in b., c., d. and e. is catalysing the reaction from an acyl donor to an amide. In a particularly preferred embodiment, the amino acid corresponding to position 158, and / or 159 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 158 of SEQ ID NO: 2 is substituted by Glu, Ser, His, Tyr, Asn, Arg, Lys, Gln, or Tyr. In another preferred embodiment, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by any other amino acid. Preferably, the amino acid corresponding to position 102 of SEQ ID NO: 2 is substituted by Asn, Ser, Tyr, or Val. The hydrolase may each be under control of a heterologous promoter or may be arranged in an operon under control of one promoter heterologous to the hydrolase, The operon may comprise further genes necessary for the production of an amide. Amino acid molecules having a certain identity to any of the sequences of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126 , include amino acid molecules having at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126. Nucleic acid molecules having a certain identity to any of the sequences of SEQ ID NO 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 , include nucleic acid molecules having at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125. A functional fragment of an amino acid molecule of the invention comprises at least 50 consecutive amino acids, preferably at least 75 consecutive amino acids, more preferably at least 100 consecutive amino acids, more preferably at least 125 consecutive amino acids, more preferably at least 150 consecutive amino acids, even more preferably at least 175 consecutive amino acids, even more preferably at least 200 consecutive amino ac- ids, even more preferably at least 225 consecutive amino acids, most preferably at least 250 consecutive amino acids of any of the sequences of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126. A further embodiment of the invention is a recombinant vector comprising the recombinant expression construct comprising i. a promoter functional in a microorganism functionally linked to a nucleic acid molecule encoding a hydro- lase wherein at least one of the promoters functionally linked to the nucleic acid molecule encoding the hydrolase is heterologous to the nucleic acid molecule encoding the hydrolase. The nucleic acid molecule encoding the hy- drolase may be under control of a heterologous promoter or may be arranged in an operon under control of one promoter heterologous to the nucleic acid molecule encoding the hydrolase. The operon may comprise further genes necessary for the production of an amide. A further embodiment of the invention is a recombinant microorganism comprising a) the recombinant expres- sion construct comprising a promoter functional in a microorganism functionally linked to a nucleic acid molecule encoding a hydrolase, wherein the promoter functionally linked to the nucleic acid molecule encoding the hydro- lase is heterologous to the nucleic acid molecule encoding the hydrolase or b) the recombinant vector compris- ing said recombinant expression construct. Preferably the recombinant microorganism is Rhodococcus rhodochrous, Aerococcus sp., Aspergillus sp., Ash- bya gossypii, Bacillus pumilus, Bacillus subtilis, Bacteroides thetaiotaomicron, Clostridium algidicarnis, Coryne- bacterium efficiens, Corynebacterium glutamicum, Escherichia coli, Haloferax volcanii, Lactobacillus casei, Methanocaldococcus jannaschii, Methanothermobacter thermautotrophicus, Myceliophthora thermophila, Pichia pastoris, Pseudomonas synxantha, Pseudomonas azotoformans, Pseudomonas jluorescens, Pseudomonas ovalis, Pseudomonas stutzeri, Pseudomonas acidovolans, Pseudomonas mucidolens, Pseudomonas testos- teroni, Pseudomonas aeruginosa, Pseudozyma tsukubaensis, Ralstonia eutropha, Rhodobacter sphaeroides, Rhodococcus opacus, Saccharomyces cerevisiae, Shigella boydii, Sinorhizobium meliloti, Streptomyces antibi- oticus, Streptomyces avermitilis, Streptomyces cacaoi, Streptomyces coelicolor, Streptomyces flavelus, Strepto- myces griseolus, Streptomyces lavendulae, Streptomyces lividans, Streptomyces olivaceus, Streptomyces ta- nashiensis, Streptomyces virginiae, Streptomyces viridochromogenes, Thermoplasma acidophilum, Vibrio natrigens or Yarrowia lipolytica. Especially preferred recombinant microorganisms are Bacillus subtilis, Corynebacterium glutamicum, Esche- richia coli, Pseudomonas aeruginosa, Pseudomonas putida, Rhodobacter sphaeroides, Rhodococcus opacus, Saccharomyces cerevisiae, Pichia pastoris, Aspergilluzs sp., Ashbya gossypii, and Yarrowia lipolytica. Another embodiment of the invention is a method of culturing or growing the recombinant microorganisms as defined above comprising inoculating a culture medium with one or more of said recombinant microorganisms and culturing or growing said recombinant microorganism in culture medium comprising an acyl donor. Another embodiment of the invention is the use of the recombinant microorganism as defined above or the com- position as defined above for the whole cell bio-conversion of an acyl donor to an amide. Another embodiment of the invention is a process for whole cell bio-conversion of an acyl donor to an amide comprising the steps of I) growing the recombinant microorganism as defined above in a fermenter comprising an acyl donor, an amine, a medium suitable for growing said recombinant microorganism and a C-source, and II) recovering an amide from the fermentation broth obtained in I). Another embodiment of the invention is a process for whole cell bio-conversion of an acyl donor to an amide comprising the step of i) growing the recombinant microorganism as defined above in a fermenter comprising a medium suitable for growing said recombinant microorganism and a C-source, and ii) recovering the recombinant microorganism from the fermenter, and iii) performing a whole cell bio-conversion in a medium by supplementing an acyl donor, and iv) recovering an amide from the medium obtained in iii). DEFINITIONS It is to be understood that this invention is not limited to the particular methodology or protocols. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention which will be limited only by the appended claims. It must be noted that as used herein and in the appended claims, the singular forms "a," "and," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a vector" is a reference to one or more vectors and includes equivalents thereof known to those skilled in the art, and so forth. The term "about" is used herein to mean approximately, roughly, around, or in the region of. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20 percent, preferably 10 percent up or down (higher or lower). As used herein, the word "or" means any one member of a particular list and also includes any combination of members of that list. The words "comprise," "comprising," "include," "including," and "includes" when used in this specification and in the following claims are intended to specify the presence of one or more stated fea- tures, integers, components, or steps, but they do not preclude the presence or addition of one or more other features, integers, components, steps, or groups thereof. For clarity, certain terms used in the specification are defined and used as follows: Antiparallel: "Antiparallel" refers herein to two nucleotide sequences paired through hydrogen bonds between complementary base residues with phosphodiester bonds running in the 5'-3' direction in one nucleotide se- quence and in the 3'-5' direction in the other nucleotide sequence. Antisense: The term "antisense" refers to a nucleotide sequence that is inverted relative to its normal orientation for transcription or function and so expresses an RNA transcript that is complementary to a target gene mRNA molecule expressed within the host cell (e.g., it can hybridize to the target gene mRNA molecule or single stranded genomic DNA through Watson-Crick base pairing) or that is complementary to a target DNA molecule such as, for example genomic DNA present in the host cell. Coding region: As used herein the term "coding region" when used in reference to a structural gene refers to the nucleotide sequences which encode the amino acids found in the nascent polypeptide as a result of translation of a mRNA molecule. The coding region is bounded, in eukaryotes, on the 5'-side by the nucleotide triplet "ATG" which encodes the initiator methionine and on the 3'-side by one of the three triplets which specify stop codons (i.e., TAA, TAG, TGA). In addition to containing introns, genomic forms of a gene may also include sequences located on both the 5'- and 3'-end of the sequences which are present on the RNA transcript. These sequences are referred to as "flanking" sequences or regions (these flanking sequences are located 5' or 3' to the non- translated sequences present on the mRNA transcript). The 5'-flanking region may contain regulatory se- quences such as promoters and enhancers which control or influence the transcription of the gene. The 3'-flank- ing region may contain sequences which direct the termination of transcription, post-transcriptional cleavage and polyadenylation. Complementary: "Complementary" or "complementarity" refers to two nucleotide sequences which comprise antiparallel nucleotide sequences capable of pairing with one another (by the base-pairing rules) upon formation of hydrogen bonds between the complementary base residues in the tiparallel nucleotide sequences. For exam- ple, the sequence 5'-AGT-3' is complementary to the sequence 5'-ACT-3'. Complementarity can be "partial" or "total." "Partial" complementarity is where one or more nucleic acid bases are not matched according to the base pairing rules. "Total" or "complete" complementarity between nucleic acid molecules is where each and every nucleic acid base is matched with another base under the base pairing rules. The degree of complemen- tarity between nucleic acid molecule strands has significant effects on the efficiency and strength of hybridiza- tion between nucleic acid molecule strands. A "complement" of a nucleic acid sequence as used herein refers to a nucleotide sequence whose nucleic acid molecules show total complementarity to the nucleic acid molecules of the nucleic acid sequence. Donor DNA molecule: As used herein the terms “donor DNA molecule”, “repair DNA molecule” or “template DNA molecule” all used interchangeably herein mean a DNA molecule having a sequence that is to be intro- duced into the genome of a cell. It may be flanked at the 5’ and / or 3’ end by sequences homologous or identical to sequences in the target region of the genome of said cell. It may comprise sequences not naturally occurring in the respective cell such as ORFs, non-coding RNAs or regulatory elements that shall be introduced into the target region or it may comprise sequences that are homologous to the target region except for at least one mu- tation, a gene edit: The sequence of the donor DNA molecule may be added to the genome or it may replace a sequence in the genome of the length of the donor DNA sequence. Double-stranded RNA: A "double-stranded RNA” molecule or “dsRNA" molecule comprises a sense RNA frag- ment of a nucleotide sequence and an antisense RNA fragment of the nucleotide sequence, which both com- prise nucleotide sequences complementary to one another, thereby allowing the sense and antisense RNA frag- ments to pair and form a double-stranded RNA molecule. Endogenous: An "endogenous" nucleotide sequence refers to a nucleotide sequence, which is present in the genome of the untransformed cell. Expression: "Expression" refers to the biosynthesis of a gene product, preferably to the transcription and / or translation of a nucleotide sequence, for example an endogenous gene or a heterologous gene, in a cell. For example, in the case of a structural gene, expression involves transcription of the structural gene into mRNA and - optionally - the subsequent translation of mRNA into one or more polypeptides. In other cases, expression may refer only to the transcription of the DNA harboring an RNA molecule. Expression construct: "Expression construct" as used herein means a DNA sequence capable of directing ex- pression of a particular nucleotide sequence in a cell, comprising a promoter functional in said cell into which it will be introduced, operatively linked to the nucleotide sequence of interest which is – optionally - operatively linked to termination signals. If translation is required, it also typically comprises sequences required for proper translation of the nucleotide sequence. The coding region may code for a protein of interest but may also code for a functional RNA of interest, for example RNAa, siRNA, snoRNA, snRNA, microRNA, ta-siRNA or any other noncoding regulatory RNA, in the sense or antisense direction. The expression construct comprising the nucleo- tide sequence of interest may be chimeric, meaning that one or more of its components is heterologous with respect to one or more of its other components. The expression construct may also be one, which is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Typically, however, the expression construct is heterologous with respect to the host, i.e., the particular DNA sequence of the ex- pression construct does not occur naturally in the host cell and must have been introduced into the host cell or an ancestor of the host cell by a transformation event. The expression of the nucleotide sequence in the expres- sion construct may be under the control of a constitutive promoter or of an inducible promoter, which initiates transcription only when the host cell is exposed to some particular external stimulus. Foreign: The term "foreign" refers to any nucleic acid molecule (e.g., gene sequence) which is introduced into the genome of a cell by experimental manipulations and may include sequences found in that cell so long as the introduced sequence contains some modification (e.g., a point mutation, the presence of a selectable marker gene, etc.) and is therefore distinct relative to the naturally-occurring sequence. Functional linkage: The term "functional linkage" or "functionally linked" is to be understood as meaning, for ex- ample, the sequential arrangement of a regulatory element (e.g. a promoter) with a nucleic acid sequence to be expressed and, if appropriate, further regulatory elements (such as e.g., a terminator) in such a way that each of the regulatory elements can fulfil its intended function to allow, modify, facilitate or otherwise influence expres- sion of said nucleic acid sequence. As a synonym the wording “operable linkage” or “operably linked” may be used. The expression may result depending on the arrangement of the nucleic acid sequences in relation to sense or antisense RNA. To this end, direct linkage in the chemical sense is not necessarily required. Genetic control sequences such as, for example, enhancer sequences, can also exert their function on the target se- quence from positions which are further away, or indeed from other DNA molecules. Preferred arrangements are those in which the nucleic acid sequence to be expressed recombinantly is positioned behind the sequence acting as promoter, so that the two sequences are linked covalently to each other. The distance between the promoter sequence and the nucleic acid sequence to be expressed recombinantly is preferably less than 200 base pairs, especially preferably less than 100 base pairs, very especially preferably less than 50 base pairs. In a preferred embodiment, the nucleic acid sequence to be transcribed is located behind the promoter in such a way that the transcription start is identical with the desired beginning of the chimeric RNA of the inven- tion. Functional linkage, and an expression construct, can be generated by means of customary recombination and cloning techniques as described (e.g., in Maniatis T, Fritsch EF and Sambrook J (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor (NY); Silhavy et al. (1984) Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor (NY); Ausubel et al. (1987) Current Protocols in Molecular Biology, Greene Publishing Assoc. and Wiley Interscience). However, further sequences, which, for example, act as a linker with specific cleavage sites for restriction enzymes, or as a signal peptide, may also be positioned between the two sequences. The insertion of sequences may also lead to the expression of fusion proteins. Preferably, the expression construct, consisting of a linkage of a regulatory region for example a promoter and nucleic acid sequence to be expressed, can exist in a vector-integrated form and be inserted into a genome, for example by transformation. Gene: The term "gene" refers to a region operably joined to appropriate regulatory sequences capable of regu- lating the expression of the gene product (e.g., a polypeptide or a functional RNA) in some manner. A gene in- cludes untranslated regulatory regions of DNA (e.g., promoters, enhancers, repressors, etc.) preceding (up- stream) and following (downstream) the coding region (open reading frame, ORF) as well as, where applicable, intervening sequences (i.e., introns) between individual coding regions (i.e., exons). The term "structural gene" as used herein is intended to mean a DNA sequence that is transcribed into mRNA which is then translated into a sequence of amino acids characteristic of a specific polypeptide. “Gene edit” when used herein means the introduction of a specific mutation at a specific position of the genome of a cell. The gene edit may be introduced by precise editing applying more advanced technologies e.g. using a CRISPR Cas system and a donor DNA, or a CRISPR Cas system linked to mutagenic activity such as a deami- nase (WO15133554, WO17070632). Genome and genomic DNA: The terms “genome” or “genomic DNA” is referring to the heritable genetic infor- mation of a host organism. Said genomic DNA comprises the DNA of the nucleus (also referred to as chromoso- mal DNA) but also the DNA of the plastids (e.g., chloroplasts) and other cellular organelles (e.g., mitochondria). Preferably the terms genome or genomic DNA is referring to the chromosomal DNA of the nucleus. Heterologous: The term "heterologous” with respect to a nucleic acid molecule or DNA refers to a nucleic acid molecule which is operably linked to, or is manipulated to become operably linked to, a second nucleic acid mol- ecule, e.g. a promoter to which it is not operably linked in nature, e.g. in the genome of a WT cell, or to which it is operably linked at a different location or position in nature, e.g. in the genome of a WT cell. Preferably the term "heterologous” with respect to a nucleic acid molecule or DNA refers to a nucleic acid mole- cule which is operably linked to, or is manipulated to become operably linked to, a second nucleic acid mole- cule, e.g. a promoter or an open reading frame to which it is not operably linked in nature. A heterologous expression construct comprising a nucleic acid molecule and one or more regulatory nucleic acid molecule (such as a promoter or a transcription termination signal) linked thereto for example is a con- structs originating by experimental manipulations in which either a) said nucleic acid molecule, or b) said regula- tory nucleic acid molecule or c) both (i.e. (a) and (b)) is not located in its natural (native) genetic environment or has been modified by experimental manipulations, an example of a modification being a substitution, addition, deletion, inversion or insertion of one or more nucleotide residues. Natural genetic environment refers to the natural chromosomal locus in the organism of origin, or to the presence in a genomic library. In the case of a genomic library, the natural genetic environment of the sequence of the nucleic acid molecule is preferably re- tained, at least in part. The environment flanks the nucleic acid sequence at least at one side and has a se- quence of at least 50 bp, preferably at least 500 bp, especially preferably at least 1,000 bp, very especially pref- erably at least 5,000 bp, in length. A naturally occurring expression construct - for example the naturally occur- ring combination of a promoter with the corresponding gene - becomes a transgenic expression construct when it is modified by non-natural, synthetic “artificial” methods such as, for example, mutagenization. Such methods have been described (US 5,565,350; WO 00 / 15815). For example, a protein encoding nucleic acid molecule operably linked to a promoter, which is not the native promoter of this molecule, is considered to be heterolo- gous with respect to the promoter. Preferably, heterologous DNA is not endogenous to or not naturally associ- ated with the cell into which it is introduced, but has been obtained from another cell or has been synthesized. Heterologous DNA also includes an endogenous DNA sequence, which contains some modification, non-natu- rally occurring, multiple copies of an endogenous DNA sequence, or a DNA sequence which is not naturally as- sociated with another DNA sequence physically linked thereto. Generally, although not necessarily, heterolo- gous DNA encodes RNA or proteins that are not normally produced by the cell into which it is expressed. Hybridization: The term "hybridization" as defined herein is a process wherein substantially complementary nu- cleotide sequences anneal to each other. The hybridisation process can occur entirely in solution, i.e. both com- plementary nucleic acids are in solution. The hybridisation process can also occur with one of the complemen- tary nucleic acids immobilised to a matrix such as magnetic beads, Sepharose beads or any other resin. The hybridisation process can furthermore occur with one of the complementary nucleic acids immobilised to a solid support such as a nitro-cellulose or nylon membrane or immobilised by e.g. photolithography to, for example, a siliceous glass support (the latter known as nucleic acid arrays or microarrays or as nucleic acid chips). In order to allow hybridisation to occur, the nucleic acid molecules are generally thermally or chemically denatured to melt a double strand into two single strands and / or to remove hairpins or other secondary structures from single stranded nucleic acids. The term “stringency” refers to the conditions under which a hybridisation takes place. The stringency of hybridi- sation is influenced by conditions such as temperature, salt concentration, ionic strength and hybridisation buffer composition. Generally, low stringency conditions are selected to be about 30°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. Medium stringency conditions are when the temperature is 20°C below Tm, and high stringency conditions are when the temperature is 10°C below Tm. High stringency hybridisation conditions are typically used for isolating hybridising sequences that have high sequence similarity to the target nucleic acid sequence. However, nucleic acids may deviate in sequence and still encode a substantially identical polypeptide, due to the degeneracy of the genetic code. Therefore, medium stringency hybridisation conditions may sometimes be needed to identify such nucleic acid molecules. The “Tm” is the temperature under defined ionic strength and pH, at which 50% of the target sequence hybrid- ises to a perfectly matched probe. The Tm is dependent upon the solution conditions and the base composition and length of the probe. For example, longer sequences hybridise specifically at higher temperatures. The maxi- mum rate of hybridisation is obtained from about 16°C up to 32°C below Tm. The presence of monovalent cati- ons in the hybridisation solution reduce the electrostatic repulsion between the two nucleic acid strands thereby promoting hybrid formation; this effect is visible for sodium concentrations of up to 0.4M (for higher concentra- tions, this effect may be ignored). Formamide reduces the melting temperature of DNA-DNA and DNA-RNA du- plexes with 0.6 to 0.7°C for each percent formamide, and addition of 50% formamide allows hybridisation to be performed at 30 to 45°C, though the rate of hybridisation will be lowered. Base pair mismatches reduce the hy- bridisation rate and the thermal stability of the duplexes. On average and for large probes, the Tm decreases about 1°C per % base mismatch. The Tm may be calculated using the following equations, depending on the types of hybrids: DNA-DNA hybrids (Meinkoth and Wahl, Anal. Biochem., 138: 267-284, 1984): Tm= 81.5°C + 16.6xlog[Na+]a + 0.41x%[G / Cb] – 500x[Lc]-1 – 0.61x% formamide DNA-RNA or RNA-RNA hybrids: Tm= 79.8 + 18.5 (log10[Na+]a) + 0.58 (%G / Cb) + 11.8 (%G / Cb)2 - 820 / Lc oligo-DNA or oligo-RNAd hybrids: For <20 nucleotides: Tm= 2 (ln) For 20–35 nucleotides: Tm= 22 + 1.46 (ln ) a or for other monovalent cation, but only accurate in the 0.01–0.4 M range. b only accurate for %GC in the 30% to 75% range. c L = length of duplex in base pairs. d Oligo, oligonucleotide; ln, effective length of primer = 2×(no. of G / C)+(no. of A / T). Non-specific binding may be controlled using any one of a number of known techniques such as, for example, blocking the membrane with protein containing solutions, additions of heterologous RNA, DNA, and SDS to the hybridisation buffer, and treatment with RNase. For non-related probes, a series of hybridizations may be per- formed by varying one of (i) progressively lowering the annealing temperature (for example from 68°C to 42°C) or (ii) progressively lowering the formamide concentration (for example from 50% to 0%). The skilled artisan is aware of various parameters which may be altered during hybridisation and which will either maintain or change the stringency conditions. Besides the hybridisation conditions, specificity of hybridisation typically also depends on the function of post- hybridisation washes. To remove background resulting from non-specific hybridisation, samples are washed with dilute salt solutions. Critical factors of such washes include the ionic strength and temperature of the final wash solution: the lower the salt concentration and the higher the wash temperature, the higher the stringency of the wash. Wash conditions are typically performed at or below hybridisation stringency. A positive hybridisa- tion gives a signal that is at least twice of that of the background. Generally, suitable stringent conditions for nu- cleic acid hybridisation assays or gene amplification detection procedures are as set forth above. More or less stringent conditions may also be selected. The skilled artisan is aware of various parameters which may be al- tered during washing and which will either maintain or change the stringency conditions. For example, typical high stringency hybridisation conditions for DNA hybrids longer than 50 nucleotides encom- pass hybridisation at 65°C in 1x SSC or at 42°C in 1x SSC and 50% formamide, followed by washing at 65°C in 0.3x SSC. Examples of medium stringency hybridisation conditions for DNA hybrids longer than 50 nucleotides encompass hybridisation at 50°C in 4x SSC or at 40°C in 6x SSC and 50% formamide, followed by washing at 50°C in 2x SSC. The length of the hybrid is the anticipated length for the hybridising nucleic acid. When nucleic acids of known sequence are hybridised, the hybrid length may be determined by aligning the sequences and identifying the conserved regions described herein.1×SSC is 0.15M NaCl and 15mM sodium citrate; the hybrid- isation solution and wash solutions may additionally include 5x Denhardt's reagent, 0.5-1.0% SDS, 100 μg / ml denatured, fragmented salmon sperm DNA, 0.5% sodium pyrophosphate. Another example of high stringency conditions is hybridisation at 65°C in 0.1x SSC comprising 0.1 SDS and optionally 5x Denhardt's reagent, 100 μg / ml denatured, fragmented salmon sperm DNA, 0.5% sodium pyrophosphate, followed by the washing at 65°C in 0.3x SSC. For the purposes of defining the level of stringency, reference can be made to Sambrook et al. (2001) Molecular Cloning: a laboratory manual, 3rd Edition, Cold Spring Harbor Laboratory Press, CSH, New York or to Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989 and yearly updates). “Identity”: “Identity” when used in respect to the comparison of two or more nucleic acid or amino acid molecules means that the sequences of said molecules share a certain degree of sequence similarity, the sequences be- ing partially identical. Enzyme variants may be defined by their sequence identity when compared to a parent enzyme. Sequence identity usually is provided as “% sequence identity” or “% identity”. To determine the percent-identity between two amino acid sequences in a first step a pairwise sequence alignment is generated between those two se- quences, wherein the two sequences are aligned over their complete length (i.e., a pairwise global alignment). The alignment is generated with a program implementing the Needleman and Wunsch algorithm (J. Mol. Biol. (1979) 48, p.443-453), preferably by using the program “NEEDLE” (The European Molecular Biology Open Software Suite (EMBOSS)) with the programs default parameters (gapopen=10.0, gapextend=0.5 and ma- trix=EBLOSUM62). The preferred alignment for the purpose of this invention is that alignment, from which the highest sequence identity can be determined. The following example is meant to illustrate two nucleotide sequences, but the same calculations apply to pro- tein sequences: Seq A: AAGATACTG length: 9 bases Seq B: GATCTGA length: 7 bases Hence, the shorter sequence is sequence B. Producing a pairwise global alignment which is showing both sequences over their complete lengths results in Seq A: AAGATACTG- ||| ||| Seq B: --GAT-CTGA The “I” symbol in the alignment indicates identical residues (which means bases for DNA or amino acids for pro- teins). The number of identical residues is 6. The “-” symbol in the alignment indicates gaps. The number of gaps introduced by alignment within the Seq B is 1. The number of gaps introduced by alignment at borders of Seq B is 2, and at borders of Seq A is 1. The alignment length showing the aligned sequences over their complete length is 10. Producing a pairwise alignment which is showing the shorter sequence over its complete length according to the invention consequently results in: Seq A: GATACTG- ||| ||| Seq B: GAT-CTGA Producing a pairwise alignment which is showing sequence A over its complete length according to the inven- tion consequently results in: Seq A: AAGATACTG ||| ||| Seq B: --GAT-CTG Producing a pairwise alignment which is showing sequence B over its complete length according to the inven- tion consequently results in: Seq A: GATACTG- ||| ||| Seq B: GAT-CTGA The alignment length showing the shorter sequence over its complete length is 8 (one gap is present which is factored in the alignment length of the shorter sequence). Accordingly, the alignment length showing Seq A over its complete length would be 9 (meaning Seq A is the sequence of the invention). Accordingly, the alignment length showing Seq B over its complete length would be 8 (meaning Seq B is the sequence of the invention). After aligning two sequences, in a second step, an identity value is determined from the alignment produced. For purposes of this description, percent identity is calculated by %-identity = (identical residues / length of the alignment region which is showing the respective sequence of this invention over its complete length) *100. Thus, sequence identity in relation to comparison of two amino acid sequences according to this embodiment is calculated by dividing the number of identical residues by the length of the alignment region which is showing the respective sequence of this invention over its complete length. This value is multiplied with 100 to give “%- identity”. According to the example provided above, %-identity is: for Seq A being the sequence of the invention (6 / 9) * 100 = 66.7 %; for Seq B being the sequence of the invention (6 / 8) * 100 =75%. InDel is a term for the random insertion or deletion of bases in the genome of an organism associated with the repair of a DSB by NHEJ. It is classified among small genetic variations, measuring from 1 to 10000 base pairs in length. As used herein it refers to random insertion or deletion of bases in or in the close vicinity (e.g. less than 1000 bp, 900 bp, 800 bp, 700 bp, 600 bp, 500 bp, 400 bp, 300 bp, 250 bp, 200 bp, 150 bp, 100 bp, 50 bp, 40 bp, 30 bp, 25 bp, 20 bp, 15 bp, 10 bp or 5 bp up and / or downstream) of the target site. The term “Introducing”, “introduction” and the like with respect to the introduction of a donor DNA molecule in the target site of a target DNA means any introduction of the sequence of the donor DNA molecule into the tar- get region for example by the physical integration of the donor DNA molecule or a part thereof into the target region or the introduction of the sequence of the donor DNA molecule or a part thereof into the target region wherein the donor DNA is used as template for a polymerase. Intron: refers to sections of DNA (intervening sequences) within a gene that do not encode part of the protein that the gene produces, and that is spliced out of the mRNA that is transcribed from the gene before it is ex- ported from the cell nucleus. Intron sequence refers to the nucleic acid sequence of an intron. Thus, introns are those regions of DNA sequences that are transcribed along with the coding sequence (exons) but are removed during the formation of mature mRNA. Introns can be positioned within the actual coding region or in either the 5’ or 3’ untranslated leaders of the pre-mRNA (unspliced mRNA). Introns in the primary transcript are excised and the coding sequences are simultaneously and precisely ligated to form the mature mRNA. The junctions of introns and exons form the splice site. The sequence of an intron begins with GU and ends with AG. Further- more, in plants, two examples of AU-AC introns have been described: the fourteenth intron of the RecA-like pro- tein gene and the seventh intron of the G5 gene from Arabidopsis thaliana are AT-AC introns. Pre-mRNAs con- taining introns have three short sequences that are –beside other sequences- essential for the intron to be ac- curately spliced. These sequences are the 5’ splice-site, the 3’ splice-site, and the branchpoint. mRNA splicing is the removal of intervening sequences (introns) present in primary mRNA transcripts and joining or ligation of exon sequences. This is also known as cis-splicing which joins two exons on the same RNA with the removal of the intervening sequence (intron). The functional elements of an intron is comprising sequences that are recog- nized and bound by the specific protein components of the spliceosome (e.g. splicing consensus sequences at the ends of introns). The interaction of the functional elements with the spliceosome results in the removal of the intron sequence from the premature mRNA and the rejoining of the exon sequences. Introns have three short sequences that are essential -although not sufficient- for the intron to be accurately spliced. These sequences are the 5´ splice site, the 3´ splice site and the branch point. The branchpoint sequence is important in splicing and splice-site selection. The branchpoint sequence is usually located 10-60 nucleotides upstream of the 3´ splice site. Isogenic: organisms, which are genetically identical, except that they may differ by the presence or absence of a heterologous DNA sequence. Isolated: The term "isolated" as used herein means that a material has been removed by the hand of man and exists apart from its original, native environment and is therefore not a product of nature. An isolated material or molecule (such as a DNA molecule or enzyme) may exist in a purified form or may exist in a non-native environ- ment such as, for example, in a transgenic host cell or a cell extract. For example, a naturally occurring polynu- cleotide or polypeptide present in a living cell is not isolated, but the same polynucleotide or polypeptide, sepa- rated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides can be part of a vector and / or such polynucleotides or polypeptides could be part of a composition and would be iso- lated in that such a vector or composition is not part of its original environment. Preferably, the term "isolated" when used in relation to a nucleic acid molecule, as in "an isolated nucleic acid sequence" refers to a nucleic acid sequence that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in its natural source. Isolated nucleic acid molecule is nucleic acid molecule present in a form or setting that is different from that in which it is found in nature. In contrast, non-isolated nucleic acid mole- cules are nucleic acid molecules such as DNA and RNA, which are found in the state they exist in nature. For example, a given DNA sequence (e.g., a gene) is found on the host cell chromosome in proximity to neighbour- ing genes; RNA sequences, such as a specific mRNA sequence encoding a specific protein, are found in the cell as a mixture with numerous other mRNAs, which encode a multitude of proteins. However, an isolated nu- cleic acid sequence comprising for example SEQ ID NO: 2 includes, by way of example, such nucleic acid se- quences in cells which ordinarily contain SEQ ID NO:2 where the nucleic acid sequence is in a chromosomal or extrachromosomal location different from that of natural cells or is otherwise flanked by a different nucleic acid sequence than that found in nature. The isolated nucleic acid sequence may be present in single-stranded or double-stranded form. When an isolated nucleic acid sequence is to be utilized to express a protein, the nucleic acid sequence will contain at a minimum at least a portion of the sense or coding strand (i.e., the nucleic acid sequence may be single-stranded). Alternatively, it may contain both the sense and anti-sense strands (i.e., the nucleic acid sequence may be double-stranded). Minimal Promoter: promoter elements, particularly a TATA element, that are inactive or that have greatly re- duced promoter activity in the absence of upstream activation. In the presence of a suitable transcription factor, the minimal promoter functions to permit transcription. Non-coding: The term "non-coding" refers to sequences of nucleic acid molecules that do not encode part or all of an expressed protein. Non-coding sequences include but are not limited to introns, enhancers, promoter re- gions, 3' untranslated regions, and 5' untranslated regions. Nucleic acids and nucleotides: The terms "Nucleic Acids" and "Nucleotides" refer to naturally occurring or syn- thetic or artificial nucleic acid or nucleotides. The terms “nucleic acids” and "nucleotides” comprise deoxyribonu- cleotides or ribonucleotides or any nucleotide analogue and polymers or hybrids thereof in either single- or dou- ble-stranded, sense or antisense form. Unless otherwise indicated, a particular nucleic acid sequence also im- plicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and com- plementary sequences, as well as the sequence explicitly indicated. The term "nucleic acid" is used inter- changeably herein with "gene", "cDNA, "mRNA", "oligonucleotide," and "polynucleotide". Nucleotide analogues include nucleotides having modifications in the chemical structure of the base, sugar and / or phosphate, includ- ing, but not limited to, 5-position pyrimidine modifications, 8-position purine modifications, modifications at cyto- sine exocyclic amines, substitution of 5-bromo-uracil, and the like; and 2'-position sugar modifications, including but not limited to, sugar-modified ribonucleotides in which the 2'-OH is replaced by a group selected from H, OR, R, halo, SH, SR, NH2, NHR, NR2, or CN. Short hairpin RNAs (shRNAs) also can comprise non-natural ele- ments such as non-natural bases, e.g., ionosin and xanthine, non-natural sugars, e.g., 2'-methoxy ribose, or non-natural phosphodiester linkages, e.g., methylphosphonates, phosphorothioates and peptides. Nucleic acid sequence: The phrase "nucleic acid sequence" refers to a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5'- to the 3'-end. It includes chromosomal DNA, self- replicating plasmids, infectious polymers of DNA or RNA and DNA or RNA that performs a primarily structural role. "Nucleic acid sequence" also refers to a consecutive list of abbreviations, letters, characters or words, which represent nucleotides. In one embodiment, a nucleic acid can be a "probe" which is a relatively short nu- cleic acid, usually less than 100 nucleotides in length. Often a nucleic acid probe is from about 50 nucleotides in length to about 10 nucleotides in length. A "target region" of a nucleic acid is a portion of a nucleic acid that is identified to be of interest. A "coding region" of a nucleic acid is the portion of the nucleic acid, which is tran- scribed and translated in a sequence-specific manner to produce into a particular polypeptide or protein when placed under the control of appropriate regulatory sequences. The coding region is said to encode such a poly- peptide or protein. Oligonucleotide: The term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxy- ribonucleic acid (DNA) or mimetics thereof, as well as oligonucleotides having non-naturally occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms be- cause of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases. An oligonucleotide preferably includes two or more nucleomonomers covalently coupled to each other by linkages (e.g., phosphodiesters) or substitute linkages. Overhang: An "overhang" is a relatively short single-stranded nucleotide sequence on the 5'- or 3'-hydroxyl end of a double-stranded oligonucleotide molecule (also referred to as an "extension," "protruding end," or "sticky end"). Polypeptide: The terms "polypeptide", "peptide", "oligopeptide", "polypeptide", "gene product", "expression prod- uct" and "protein" are used interchangeably herein to refer to a polymer or oligomer of consecutive amino acid residues. Pre-protein: Protein, which is normally targeted to a cellular organelle, such as a chloroplast, and still comprising its transit peptide. “Precise” with respect to the introduction of a donor DNA molecule in target region means that the sequence of the donor DNA molecule is introduced into the target region without any InDels, duplications or other mutations as compared to the unaltered DNA sequence of the target region that are not comprised in the donor DNA mol- ecule sequence. Primary transcript: The term “primary transcript” as used herein refers to a premature RNA transcript of a gene. A “primary transcript” for example still comprises introns and / or is not yet comprising a polyA tail or a cap struc- ture and / or is missing other modifications necessary for its correct function as transcript such as for example trimming or editing. Promoter: The terms "promoter", or "promoter sequence" are equivalents and as used herein, refer to a DNA sequence which when ligated to a nucleotide sequence of interest is capable of controlling the transcription of the nucleotide sequence of interest into RNA. A promoter is located 5' (i.e., upstream), proximal to the transcrip- tional start site of a nucleotide sequence of interest whose transcription into mRNA it controls and provides a site for specific binding by RNA polymerase and other transcription factors for initiation of transcription. Said promoter comprises for example the at least 10 kb, for example 5 kb or 2 kb proximal to the transcription start site. It may also comprise the at least 1500 bp proximal to the transcriptional start site, preferably the at least 1000 bp, more preferably the at least 500 bp, even more preferably the at least 400 bp, the at least 300 bp, the at least 200 bp or the at least 100 bp. In a further preferred embodiment, the promoter comprises the at least 50 bp proximal to the transcription start site, for example, at least 25 bp. The promoter does not comprise exon and / or intron regions or 5´ untranslated regions. The promoter may for example be heterologous or homologous to the respective cell. A polynucleotide sequence is "heterologous to" an organism or a second polynucleotide sequence if it originates from a foreign species, or, if from the same species, is modified from its original form. For example, a promoter operably linked to a heterologous coding sequence refers to a coding sequence from a species different from that from which the promoter was derived, or, if from the same species, a coding se- quence which is not naturally associated with the promoter (e.g. a genetically engineered coding sequence or an allele from a different ecotype or variety). Suitable promoters can be derived from genes of the host cells where expression should occur or from pathogens for this host cells (e.g. viruses). If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. The term "constitutive" when made in reference to a promoter or the expression derived from a promoter means that the promoter is capable of directing transcription of an operably linked nucleic acid molecule in the absence of a stimulus (e.g., heat shock, chemicals, light, etc.) in cells throughout substantially the entire lifespan of said cell. Promoter specificity: The term “specificity” when referring to a promoter means the pattern of expression con- ferred by the respective promoter. The specificity describes the developmental status of a cell, in which the pro- moter is conferring expression of the nucleic acid molecule under the control of the respective promoter. Speci- ficity of a promoter may also comprise the environmental conditions, under which the promoter may be activated or down-regulated such as induction or repression by biological or environmental stresses such as cold, drought or infection. Purified: As used herein, the term "purified" refers to molecules, either nucleic or amino acid sequences that are removed from their natural environment, isolated or separated. "Substantially purified" molecules are at least 60% free, preferably at least 75% free, and more preferably at least 90% free from other components with which they are naturally associated. A purified nucleic acid sequence may be an isolated nucleic acid sequence. Recombinant: The term "recombinant" with respect to nucleic acid molecules refers to nucleic acid molecules produced by recombinant DNA techniques. Recombinant nucleic acid molecules may also comprise molecules, which as such does not exist in nature but are modified, changed, mutated or otherwise manipulated by man. Preferably, a "recombinant nucleic acid molecule" is a non-naturally occurring nucleic acid molecule that differs in sequence from a naturally occurring nucleic acid molecule by at least one nucleic acid. A “recombinant nu- cleic acid molecule” may also comprise a “recombinant construct” which comprises, preferably operably linked, a sequence of nucleic acid molecules not naturally occurring in that order. Preferred methods for producing said recombinant nucleic acid molecule may comprise cloning techniques, directed or non-directed mutagenesis, synthesis or recombination techniques. Sense: The term "sense" is understood to mean a nucleic acid molecule having a sequence which is comple- mentary or identical to a target sequence, for example a sequence which binds to a protein transcription factor and which is involved in the expression of a given gene. According to a preferred embodiment, the nucleic acid molecule comprises a gene of interest and elements allowing the expression of the said gene of interest. Significant increase or decrease: An increase or decrease, for example in enzymatic activity or in gene expres- sion, that is larger than the margin of error inherent in the measurement technique, preferably an increase or decrease by about 2-fold or greater of the activity of the control enzyme or expression in the control cell, more preferably an increase or decrease by about 5-fold or greater, and most preferably an increase or decrease by about 10-fold or greater. Small nucleic acid molecules: “small nucleic acid molecules” are understood as molecules consisting of nucleic acids or derivatives thereof such as RNA or DNA. They may be double-stranded or single-stranded and are be- tween about 15 and about 30 bp, for example between 15 and 30 bp, more preferred between about 19 and about 26 bp, for example between 19 and 26 bp, even more preferred between about 20 and about 25 bp for example between 20 and 25 bp. In an especially preferred embodiment, the oligonucleotides are between about 21 and about 24 bp, for example between 21 and 24 bp. In a most preferred embodiment, the small nucleic acid molecules are about 21 bp and about 24 bp, for example 21 bp and 24 bp. Substantially complementary: In its broadest sense, the term "substantially complementary", when used herein with respect to a nucleotide sequence in relation to a reference or target nucleotide sequence, means a nucleo- tide sequence having a percentage of identity between the substantially complementary nucleotide sequence and the exact complementary sequence of said reference or target nucleotide sequence of at least 60%, more desirably at least 70%, more desirably at least 80% or 85%, preferably at least 90%, more preferably at least 93%, still more preferably at least 95% or 96%, yet still more preferably at least 97% or 98%, yet still more pref- erably at least 99% or most preferably 100% (the latter being equivalent to the term “identical” in this context). Preferably identity is assessed over a length of at least 19 nucleotides, preferably at least 50 nucleotides, more preferably the entire length of the nucleic acid sequence to said reference sequence (if not specified otherwise below). Sequence comparisons are carried out using default GAP analysis with the University of Wisconsin GCG, SEQWEB application of GAP, based on the algorithm of Needleman and Wunsch (Needleman and Wun- sch (1970) J Mol. Biol.48: 443-453; as defined above). A nucleotide sequence "substantially complementary " to a reference nucleotide sequence hybridizes to the reference nucleotide sequence under low stringency condi- tions, preferably medium stringency conditions, most preferably high stringency conditions (as defined above). “Target region” as used herein means the region close to, for example 10 bases, 20 bases, 30 bases, 40 bases, 50 bases, 60 bases, 70 bases, 80 bases, 90 bases, 100 bases, 125 bases, 150 bases, 200 bases or 500 bases or more away from the target site, or including the target site in which the sequence of the donor DNA molecule is introduced into the genome of a cell. “Target site” as used herein means the position in the genome at which a double strand break or one or a pair of single strand breaks (nicks) are induced using recombinant technologies such as Zn-finger, TALEN, restriction enzymes, homing endonucleases, RNA-guided nucleases, RNA-guided nickases such as CRISPR / Cas nucle- ases or nickases and the like. Transgene: The term "transgene" as used herein refers to any nucleic acid sequence, which is introduced into the genome of a cell by experimental manipulations. A transgene may be an "endogenous DNA sequence," or a "heterologous DNA sequence" (i.e., "foreign DNA"). The term "endogenous DNA sequence" refers to a nucleo- tide sequence, which is naturally found in the cell into which it is introduced so long as it does not contain some modification (e.g., a point mutation, the presence of a selectable marker gene, etc.) relative to the naturally-oc- curring sequence. Transgenic: The term transgenic when referring to an organism means transformed, preferably stably trans- formed, with a recombinant DNA molecule that preferably comprises a suitable promoter operatively linked to a DNA sequence of interest. Vector: As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nu- cleic acid molecule to which it has been linked. One type of vector is a genomic integrated vector, or "integrated vector", which can become integrated into the chromosomal DNA of the host cell. Another type of vector is an episomal vector, i.e., a nucleic acid molecule capable of extra-chromosomal replication. Vectors capable of di- recting the expression of genes to which they are operatively linked are referred to herein as "expression vec- tors". In the present specification, "plasmid" and "vector" are used interchangeably unless otherwise clear from the context. Expression vectors designed to produce RNAs as described herein in vitro or in vivo may contain sequences recognized by any RNA polymerase, including mitochondrial RNA polymerase, RNA pol I, RNA pol II, and RNA pol III. These vectors can be used to transcribe the desired RNA molecule in the cell according to this invention. Wild-type: The term "wild-type", "natural" or "natural origin" means with respect to an organism, polypeptide, or nucleic acid sequence, that said organism is naturally occurring or available in at least one naturally occurring organism which is not changed, mutated, or otherwise manipulated by man. EXAMPLES (A) Chemical methods 1) HPLC Analysis Conversions were determined by high pressure liquid chromatography (HPLC), equipped with a reverse station- ary phase column (Luna 5 µm C18, 100 Å, LC column 250 x 4.6 mm), and ultra high pressure liquid chromatog- raphy (UHPLC), equipped with a reverse stationary phase column (Luna Omega 1.6 µm C18, 100 Å, LC column 50 x 2.1 mm). In both cases, substrate and product were detected by UV-absorption. The following method was used for the pH assay (UHPLC):Compounds containing 2-furane moiety: 0.5 mL / min, 20 min at 30◦C, starting with 10 % MeCN to 100 % water.Water and acetonitrile contained 0.1% TFA.Compounds containing picolin moiety: 0.5 mL / min, 9 min at 30◦C, starting with 5 % MeCNto 100 % water. Water and acetonitrile contained 0.1% TFA. The following method was used for the biotransformations (HPLC):1 mL / min, 33 min at 30◦C, starting with 10 % MeCN to 100 % water. Water and acetonitrile contained 0.1% TFA.Compounds containing 2-furane moiety: 0.5 mL / min, 20 min at 30◦C, starting with 10 % MeCN to 100 % water.Water and acetonitrile contained 0.1% TFA 2) GC-MS Analysis The quality of product was determined by GC-MS using an Agilent Technologies 5975C inert XL MSD and an Agilent Technologies 7890A GC equipped with an HP-5ms column (30m x 0.25 mm x 0.25 µm). Carrier gas was helium. The following method was used:Start temp.: 100◦C, 0.5 min hold. Ramp 1: 10◦C / min to 300◦C, 0 min hold(method name: achiral). 3) NMRAll1H- and13C-spectra were measured with a Bruker Avance III 300 MHz spectrometer at 300 MHz for1H- and75 MHz for13C-NMR. 4) Synthesis of amides All presented syntheses are conducted in buffer and using SpLWt (SEQ ID NO: 2) as biocatalyst. a) Amidation of N -phenylnicotinamide In a 14 mL conical plastic tube, aniline (0.195 g, 2.09 mmol) and KPi buffer (200 mM, 10 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of conc. HCl. At the pH 7.5, CFE of SpL was added (30 mg) and the mixture was mixed until the CFE was dissolved. Then the ethylnicotinate (0.09 g, 0.6 mmol) was added and incubated at 30◦C, 120 rpm. After 26 h, the reaction was stoppedby extraction with ethyl acetate (3 x 5 mL). The combined organic phases were extracted with aqueous 2 M KOH (1 x 5 mL) and washed with brine (1 x 5 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. The crude was purified by column chro- matography with a biotage using a gradient with the eluent mixture cyclohexane and ethyl acetate. The product was in the end flushed with ethyl acetate. Yield 0.033 g (27%) Sum formula, m.w. C12H10N2O, 198.231H-NMR (300 MHz, CDCl3):δ 9.07 (d, J = 6.0, 5.9, 4.1, 3.9, 2.4, 2.0, 2.0, 0.3 Hz, 1H), 8.73 (dd, J = 4.8, 1.7 Hz, 1H), 8.23 (s, 1H), 8.19 (dt, J = 7.9, 2.0 Hz, 1H), 7.63 (d, J = 7.7 Hz, 2H), 7.46 – 7.30 (m, 3H), 7.23 – 7.11 (m, 1H).13C-NMR (75 MHz, CDCl3):δ 164.1, 152.6, 148.0, 137.6, 135.5, 131.0, 129.3, 125.2, 123.8, 120.7 b) Amidation of N -benzylnicotinamide In a 25 mL round bottomed flask, benzylamine (0.15 g, 5.1 mmol) and KPi buffer (200 mM, 16 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of conc. HCl. At the pH 7.5, CFE of SpL was added (80 mg) and the mixture was stirred until the CFE was dissolved.The water bath was adjusted to 30◦C and then the ethyl nicotinate (0.55 g, 0.97 mmol) was added andstirred. After 33 min, the reaction was stopped by extraction with ethyl acetate (3 x 8 mL). The combined or- ganic phases were extracted with aqueous 2 M KOH (1 x 5 mL) and washed with brine (1 x 8 mL). The or- ganic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase was evaporated under reduced pressure. Crude was purified via a column pasteur pipette using first the eluent mix 50% cyclo- hexane and 50% ethyl acetate to remove the impurities. The product was in the end flushed with ethyl ace- tate. Yield 0.068 g (33%) Sum formula, m.w. C13H12N2O, 212.251H-NMR (300 MHz, CDCl3):δ 8.95 (d, J = 2.3 Hz, 1H), 8.68 (dd, J = 4.9, 1.7 Hz, 1H), 8.12 (dt, J = 8.0, 2.0 Hz, 1H), 7.39 – 7.27 (m, 6H), 6.74 (s, 1H), 4.64 (d, J = 5.6 Hz, 2H).13C-NMR (75 MHz, CDCl3):δ 165.6, 152.4, 148.0, 137.9, 135.3, 130.2, 129.0, 128.1, 127.9, 123.7, 44.3 c) Amidation of N -hexylnicotinamide In a 50 mL round bottomed flask, n-hexylamine (0.35 g, 3.43 mmol) and KPi buffer (200 mM, 25 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of conc. HCl. At the pH 7.5, CFE of SpL was added (75 mg) and the mixture was stirred for 3 min. The water bath was ad-justed to 30◦C and then the ethyl-2-picolinate (0.15 g, 0.98 mmol) was added and stirred. After 45 min, thereaction was stopped by extraction with ethyl acetate (3 x 15 mL). The combined organic phases were ex- tracted with aqueous 2 M KOH (1 x 15 mL) and washed with brine (1 x 15 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. Crude was purified via a column pipette using first the eluent mix 50% cyclohexane and 50% ethyl acetate to remove the impurities. The product was in the end flushed with ethyl acetate. Yield 0.003 g (1%) Sum formula, m.w. C12H18N2O, 206.291H-NMR (300 MHz, CDCl3):δ 8.95 (d, J = 2.2 Hz, 1H), 8.72 (dd, J = 4.9, 1.7 Hz, 1H), 8.11 (dt, J = 7.9, 2.0 Hz, 1H), 7.39 (dd, J = 7.9, 4.8 Hz, 1H), 6.14 (s, 1H), 3.47 (td, J = 7.2, 5.7 Hz, 2H), 1.64 (d, J = 8.6 Hz, 2H), 1.40 – 1.27 (m, 6H), 0.89 (d, J = 6.7 Hz, 3H) d) Amidation of 5-chloro-N -benzylamide In a 25 mL round bottomed flask, benzylamine (0.28 g, 2.66 mmol) and KPi buffer (200 mM, 20 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of 85% H3PO4and 1 M NaOH. At pH 7.5, CFE of SpL was added (10 mg) and the mixture was stirred till aclear solution was observed. The water bath was adjusted to 30◦C and then the ethyl-5-chloropicolinate(0.14 g, 0.76 mmol) was added and stirred. After 90 min, the reaction was quenched with conc. HCl. The aqueous phase was extracted with ethyl acetate (3 x 5 mL). The combined organic phases were extracted with aqueous 2 M KOH (3 x 5 mL) and washed with brine (2 x 5 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pres- sure. Yield 0.164 g (88%) Sum formula, m.w. C13H11ClN2O, 246.691H-NMR (300 MHz, CDCl3):δ 8.47 (d, J = 2.4 Hz, 1H), 8.22 (s, 1H), 8.19 (d, J = 8.3 Hz, 1H), 7.83 (dd, J = 8.4, 2.4 Hz, 1H), 7.41 – 7.27 (m, 5H), 4.66 (d, J = 6.1 Hz, 2H).13C-NMR (75 MHz, CDCl3):δ 163.5, 148.1, 147.2, 138.1, 137.2, 135.2, 128.9, 128.0, 127.7, 123.5, 43.7 e) Amidation of 5-chloro-N -hexylamide In a 25 mL round bottomed flask, n-hexylamine (0.39 g, 3.85 mmol) and KPi buffer (200 mM, 20 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of 85% H3PO4and 1 M NaOH. At pH 7.5, CFE of SpL was added (10 mg) and the mixture was stirred until a clearsolution was observed. The water bath was adjusted to 30◦C and then the ethyl-5-chloropicolinate (0.21 g,1.11 mmol) was added and stirred. After 90 min, the reaction was quenched with conc. HCl. The aqueous phase was extracted with ethyl acetate (3 x 5 mL). The combined organic phases were extracted with aque- ous 2 M KOH (3 x 5 mL) and washed with brine (2 x 5 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. Yield 0.178 g (67%) Sum formula, m.w. C12H17ClN2O, 240.731H-NMR (300 MHz, CDCl3):δ 8.48 (d, J = 2.4 Hz, 1H), 8.15 (d, J = 8.3 Hz, 1H), 7.90 (s, 1H), 7.80 (dd, J = 8.4, 2.4 Hz, 1H), 3.45 (q, J = 6.8 Hz, 2H), 1.61 (q, J = 7.3 Hz, 2H), 1.40 – 1.24 (m, 6H), 0.88 (t, J = 6.7 Hz, 4H).13C-NMR (75 MHz, CDCl3):δ 163.5, 148.4, 147.1, 137.2, 134.9, 123.3, 39.7, 31.6, 29.7, 26.8, 22.7, 14.2 f) Amidation of 5-chloro-N-allylamide In a 50 mL round bottomed flask, allylamine (0.30 g, 5.31 mmol) and KPi buffer (200 mM, 20 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of conc. HCl. At pH 7.5, CFE of SpL was added (20 mg) and the mixture was stirred for 5 min. Thewater bath was adjusted to 30◦C and then the ethyl-5-chloropicolinate (0.28 g, 1.52 mmol) was addedand stirred. After 100 min, the reaction was quenched with conc. HCl. The aqueous phase was extracted ethyl acetate (3 x 10 mL). The combined organic phases were extracted with aqueous 2 M KOH (2 x 5 mL) and washed with brine (1 x 5 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. The crude was purified by column chro- matography with a biotage using a gradient and the eluents cyclohexane and ethyl acetate. Yield 0.037 g (12%) Sum formula, m.w. C9H9ClN2O, 196.631H-NMR (300 MHz, CDCl3):δ 8.49 (dd, J = 2.5, 0.7 Hz, 1H), 8.16 (dd, J = 8.4, 0.7 Hz, 1H), 7.99 (s, 1H), 7.82 (dd, J = 8.4, 2.4 Hz, 1H), 5.93 (ddt, J = 17.2, 10.2, 5.6 Hz, 1H), 5.32 – 5.13 (m, 2H), 4.10 (tt, J = 5.9, 1.6 Hz, 2H).13C-NMR (75 MHz, CDCl3):δ 163.4, 148.1, 147.3, 137.2, 135.1, 134.0, 123.4, 116.7, 42.0. g) Amidation of N-benzylpyrazin-2-carboxamide In a 25 mL round bottomed flask, benzylamine (0.49 g, 4.55 mmol) and KPi buffer (200 mM, 20 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of 85% H3PO4and 1 M NaOH. At pH 7.5, CFE of SpL was added (10 mg) and the mix-ture was stirred till a clear solution was observed. The water bath was adjusted to 30◦C and then the ethylpyrazine-2-carboxylate (0.20 g, 1.3 mmol) was added and stirred. After 40 min, the reaction was quenched with conc. HCl. The aqueous phase was extracted with ethyl acetate (3 x 10 mL). The combined organic phases were extracted with aqueous 2 M KOH (3 x 10 mL) and washed with brine (2 x 10 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. Yield 0.144 g (52%) Sum formula, m.w. C12H11N3O, 213.241H-NMR (300 MHz, CDCl3):δ 9.45 (d, J = 1.5 Hz, 1H), 8.74 (d, J = 2.5 Hz, 1H), 8.50 (td, J = 2.5, 1.5 Hz, 1H), 8.13 (s, 1H), 7.36 (d, J = 4.4 Hz, 5H), 4.68 (d, J = 6.0 Hz, 2H).13C-NMR (75 MHz, CDCl3):δ 163.0, 147.5, 144.7, 144.5, 142.7, 137.9, 128.9, 128.0, 127.8, 43.6 h) Amidation of N-hexylpyrazin-2-carboxamide In a 25 mL round bottomed flask, n-hexylamine (0.36 g, 3.6 mmol) and KPi buffer (200 mM, 14 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with conc. HCl. At pH 7.5, CFE of SpL was added (14 mg) and the mixture was stirred until the CFE was dissolved. The waterbath was adjusted to 30◦C and then the ethyl pyrazine-2-carboxylate (0.30 g, 1.03 mmol) was addedand stirred. After 47 min, no ester spot was observed by TLC and the reaction was quenched with conc. HCl. The aqueous phase was extracted ethyl acetate (3 x 10 mL). The combined organic phases were extracted with aqueous 2 M KOH (1 x 5 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. Yield 0.058 g (27%) Sum formula, m.w. C11H17N3O,1H-NMR (300 MHz, CDCl3):δ 9.41 (d, J = 1.5 Hz, 1H), 8.74 (d, J = 2.5 Hz, 1H), 8.51 (t, J = 2.0 Hz, 1H), 7.80 (s, 1H), 3.48 (q, J = 6.8 Hz, 2H), 1.63 (p, J = 7.1 Hz, 2H), 1.47 – 1.23 (m, 6H), 0.89 (q, J = 6.6, 4.8 Hz, 3H).13C-NMR (75 MHz, CDCl3):δ 163.0, 147.3, 144.8, 144.6, 142.6, 39.6, 31.6, 29.7, 26.8, 22.7, 14.2 i) Amidation of N-allylpyrazin-2-carboxamide In a 25 mL round bottomed flask, benzylamine (1.2 g, 21.06 mmol) and KPi buffer (200 mM, 120 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of conc. HCl. At pH 7.5, CFE of SpL was added (120 mg) and the mixture was stirreduntil the CFE was dissolved. The water bath was adjusted to 30◦C and then the ethyl pyrazine-2-carbox-ylate (0.14 g, 1.03 mmol) was added and stirred. After 20 min, the reaction was quenched with conc. HCl. The aqueous phase was extracted with ethyl acetate (3 x 50 mL). The combined organic phases were ex- tracted with aqueous 2 M KOH (2 x 30 mL) and washed with brine (1 x 30 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. Crude was purified via a column pasteuer pipette using first the eluent mixture 30% cyclohexane and 70% ethyl acetate. Yield 0.013 g (1%) Sum formula, m.w. C8H9N3O,163.181H-NMR (300 MHz, CDCl3):δ 9.41 (d, J = 1.5 Hz, 1H), 8.75 (d, J = 2.5 Hz, 1H), 8.52 (dd, J = 2.5, 1.5 Hz, 1H), 7.89 (s, 1H), 5.93 (ddt, J = 17.1, 10.2, 5.6 Hz, 1H), 5.37 – 5.14 (m, 2H), 4.12 (tt, J = 5.9, 1.6 Hz, 2H).13C-NMR (75 MHz, CDCl3):δ 163.0, 147.4, 144.6, 144.6, 142.7, 133.8, 117.0, 41.9 j) Amidation of N-phenylthiophene-2-carboxamide In a 25 mL round bottomed flask, aniline (0.22 g, 2.37 mmol) and KPi buffer (200 mM, 10 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 by addition of conc. HCl. At pH 7.5, CFE of SpL was added (20 mg) and the mixture was stirred until the CFE was dissolved. Then, the ethyl thiophene-2-carboxylate (0.11 g, 0.68 mmol) was added and stirred. After 20 h, no ester spot was observed on the TLC and the reaction was quenched with conc. HCl. The aqueous phase was extracted ethyl acetate (3 x 5 mL). The combined organic phases were extracted with aqueous 2 M KOH (1 x 5 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. The crude was purified by column chromatography with a biotage using a gradient and the eluents cyclohexane and ethyl acetate. Yield 0.063 g (46%) Sum formula, m.w. C11H9NOS, 203.461H-NMR (300 MHz, CDCl3):δ 7.79 (s, 1H), 7.66 – 7.59 (m, 3H), 7.54 (dd, J = 5.0, 1.2 Hz, 1H), 7.41 – 7.31 (m, 2H), 7.19 – 7.09 (m, 2H).13C-NMR (75 MHz, CDCl3):δ 160.1, 139.4, 137.7, 130.9, 129.2, 128.6, 128.0, 124.8, 120.4 k) Amidation of N-Allylthiophene-2-carboxamide In a 25 mL round bottomed flask, allylamine (1.01 g, 17.71 mmol) and KPi buffer (200 mM, 60 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of conc. HCl. At pH 7.5, CFE of SpL was added (60 mg) and the mixture was stirreduntil the CFE was dissolved. The water bath was adjusted to 30◦C and then the ethyl-2-thiophene carbox-ylate (0.22 g, 5.06 mmol) was added and stirred. After 1 h, the reaction was quenched with conc. HCl. The aqueous phase was extracted with ethyl acetate (3 x 30 mL). The combined organic phases were extracted with aqueous 2 M KOH (2 x 25 mL) and washed with brine (1 x 40 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. Crude was purified via a column pasteuer pipette using the eluent mix 40% cyclohexane and 60% ethyl acetate. Yield 0.014 g (2%) Sum formula, m.w. C8H9NOS, 167.231H-NMR (300 MHz, CDCl3):δ 7.53 (dd, J = 3.7, 1.2 Hz, 1H), 7.47 (dd, J = 5.0, 1.2 Hz, 1H), 7.07 (dd, J = 5.0, 3.7 Hz, 1H), 6.18 (s, 1H), 5.92 (ddt, J = 17.2, 10.2, 5.7 Hz, 1H), 5.31 – 5.08 (m, 2H), 4.06 (tt, J = 5.8 , 1.5 Hz, 2H).13C-NMR (75 MHz, CDCl3):δ 161.9, 138.9, 134.2, 130.0, 128.2, 127.7, 116.9, 42.5 l) Amidation of furan-2-carboxylic acid phenylamide In a 14 mL conical plastic tube, aniline (0.28 g, 3.02 mmol) and KPi buffer (200 mM, 14 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of conc. HCl. At pH 7.5, CFE of SpL was added (28 mg) and mixed until the CFE was dissolved. Then theethyl-2-furoate (0.12 g, 0.86 mmol) was added and everything was incubated at 30◦C, 120 rpm. After4.5 h, the reaction was quenched with conc. HCl. The aqueous phase was extracted ethyl acetate (3 x 8 mL). The combined organic phases were extracted with aqueous 2 M KOH (1 x 5 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. Yield 0.140 g (87%) Sum formula, m.w. C11H9NO2, 187.201H-NMR (300 MHz, CDCl3):δ 8.08 (s, 1H), 7.65 (d, J = 7.6 Hz, 2H), 7.51 (d, J = 2.0 Hz, 1H), 7.37 (t, J = 7.9 Hz, 2H), 7.24 (d, J = 3.6 Hz, 1H), 7.15 (t, J = 7.4 Hz, 1H), 6.56 (dd, J = 3.6, 1.8 Hz, 1H).13C-NMR (75 MHz, CDCl3):δ 156.2, 148.0, 144.3, 137.5, 129.3, 124.7, 120.0, 115.4, 112.8 m) Amidation of furan-2-carboxylic acid hexylamide In a 25 mL round bottomed flask, n-hexylamine (0.36 g, 3.53 mmol) and KPi buffer (200 mM, 20 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of 85% H3PO4and 1 M NaOH. At pH 7.5, CFE of SpL was added (10 mg) and the mixture was stirred till a clearsolution was observed. The water bath was adjusted to 30◦C and then the ethyl-2-furoate (0.14 g, 1.01mmol) was added and stirred. After 85 min, the reaction was quenched with conc. HCl. The aqueous phase was extracted with ethyl acetate (3 x 10 mL). The combined organic phases were extracted with aque- ous 2 M KOH (3 x 10 mL) and washed with brine (2 x 10 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. The crude was puri- fied by column chromatography with a biotage using a gradient and the eluents cyclohexane and ethyl ace- tate. Yield 0.054 g (28%) Sum formula, m.w. C11H17NO2, 195.261H-NMR (300 MHz, CDCl3):δ 7.45 – 7.37 (m, 1H), 7.09 (dd, J = 3.5, 0.9 Hz, 1H), 6.48 (dd, J = 3.5, 1.8 Hz, 1H), 6.36 (s, 1H), 3.41 (td, J = 7.2, 5.9 Hz, 2H), 1.65 – 1.53 (m, 2H), 1.42 – 1.23 (m, 6H), 0.88 (t, J = 7.1, 7.0, 6.1 Hz, 3H).13C-NMR (75 MHz, CDCl3):δ 158.5, 148.4, 143.8, 114.0, 112.2, 39.3, 31.6, 29.8, 26.7, 22.7, 14.1 n) Amidation of benzofuran-2-carboxylic acid N-phenylamide In a 14 mL conical plastic tube, aniline (0.27 g, 2.94 mmol) and KPi buffer (200 mM, 10 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of 85% H3PO4. At pH 7.5, CFE of SpL was added (10 mg) and the mixture was mixed until the CFE was dis- solved. Then, the ethyl-1-benzofuran-2-carboxylate (0.16 g, 0.84 mmol) was added and everything wasincubated at 30◦C, 120 rpm. After 20 h, the reaction was quenched with conc. HCl. The aqueous phasewas extracted with ethyl acetate (3 x 5 mL). The combined organic phases were extracted with aqueous 2 M KOH (2 x 5 mL) and washed with brine (1 x 5 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. Yield 0.180 g (90%) Sum formula, m.w. C15H11NO2, 237.261H-NMR (300 MHz, CDCl3):δ 8.36 (s, 1H), 7.75 – 7.69 (m, 3H), 7.61 – 7.54 (m, 2H), 7.48 – 7.31 (m, 4H), 7.18 (t, J = 7.4 Hz, 1H).13C-NMR (75 MHz, CDCl3):δ 156.7, 154.9, 148.6, 137.4, 129.3, 127.8, 127.4, 124.9, 124.1, 123.0, 120.1, 112.0, 111.6 o) Amidation of N-benzyl-1-benzofuran-2-carboxamide In a 14 mL conical plastic tube, benzylamine (0.12 g, 1.10 mmol) and KPi buffer (200 mM, 5 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and ajusted to 7.5 with the addition of 85% H3PO4. At the pH 7.5, CFE of SpL was added (5 mg) and the mixture was mixed until the CFE was dissolved. Then,the ethyl-1-benzofuran-2-carboxylate (0.122 g, 0.64 mmol) was added and everything was incubated at 30◦C,120 rpm. After 18 h, the reaction was quenched with conc. HCl. The aqueous phase was extracted ethyl acetate (3 x 2 mL). The combined organic phases were extracted with 2 M KOH (2 x 3 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under re- duced pressure. Yield 0.032 g (41%) Sum formula, m.w. C16H13NO2, 251.091H-NMR (300 MHz, CDCl3):δ 7.68 (dt, J = 7.7, 1.0 Hz, 1H), 7.54 – 7.22 (m, 9H), 6.94 (s, 1H), 4.68 (d, J = 5.9 Hz, 2H).13C-NMR (75 MHz, CDCl3):δ 158.9, 154.9, 148.7, 137.9, 129.0, 128.2, 127.9, 127.8, 127.1, 123.9, 122.9, 111.9, 110.8, 43.6 p) Amidation of N-hexyl-1-benzofuran-2-carboxamide In a 14 mL conical plastic tube, n-hexylamine (0.23 g, 2.23 mmol) and KPi buffer (200 mM, 10 mL at pH 7.5) were mixed together. Afterwards, the pH was measured and adjusted to 7.5 with the addition of 85% H3PO4. At pH 7.5, CFE of SpL was added (10 mg) and the mixture was mixed until the CFE was dis- solved. Then, the ethyl-1-benzofuran-2-carboxylate (0.122 g, 0.64 mmol) was added and everything wasincubated at 30◦C, 120 rpm. After 18 h, the reaction was quenched with conc. HCl. The aqueous phasewas extracted ethyl acetate (3 x 5 mL). The combined organic phases were extracted with 2 M KOH (2 x 3 mL). The organic phase was dried over Na2SO4. The Na2SO4was filtered off and the organic phase evaporated under reduced pressure. Yield 0.128 g (82%) Sum formula, m.w. C15H19NO2, 245.32 1H-NMR (300 MHz, CDCl3):δ 7.67 (d, J = 7.8 Hz, 1H), 7.52 – 7.36 (m, 3H), 7.32 – 7.27 (m, 1H), 6.64 (s, 1H), 3.48 (q, J = 6.9 Hz, 2H), 1.63 (q, J = 7.2 Hz, 2H), 1.44 – 1.24 (m, 6H), 0.89 (t, 3H). 13C-NMR (75 MHz, CDCl3):δ 159.0, 154.8, 149.1, 127.8, 126.9, 123.8, 122.9, 111.8, 110.3, 39.5, 31.6, 29.8, 26.8, 22.7, 14.2 (B) Biotechnology methods Unless denoted otherwise, all experiments were carried out at atmospheric condition. Only the preparation of the growth medium and plasmid transformations were done under antiseptical condition. 1) Shaker Incubator Incubation of any kind of flasks was done in an Infors HT Multitron Standard incubation shaker. A Thermomixer comfort (Eppendorf) was used for 1.5 mL reaction tubes for biotransforma- tion. 2) Determination of Protein Concentration, OD600and Plasmid Concentration The protein and plasmid concentration as well as the OD600was measured by an Eppendorf BioPhotometer. ) Materials and Methods Solvents and compounds were obtained from Sigma-Aldrich, Fisher Scientific, Abcr, ACROS, Roth or TCI. SDS- PAGE loading buffer, SDS-PAGE gels and SDS-PAGE ladders were supplied by BioRad or Thermo Fisher. 4) Buffer preparation for assay 7.697 g of citric acid or respectively 11.764 g of sodium citrate dihydrate were each filled to a volume of 200 mL with water Table 1: Preparation of 200 mM citrate buffer for assay. Buffers were prepared from 200 mM stock solu- tions, namely citric acid and sodium citrate dihydrate. pH Vol. citric acid [mL] Vol. sodium citrate [mL] 4 31.5 18.5 4.5 25.5 24.5 5 20.5 29.5 5.5 16 34 6 11.8 38.2 MCitricacid= 192.12 g / mol, MNacitrate= 294.10 g / mol pH val- ues were adjusted with NaOH & HCl. Table 2: Preparation of 200 mM KPi buffer in 30 mL for assay. pHtheopHrealKH2PO4K2HPO4m [g] n [mM] m [g] n [mmol] 6 6 0.70 5.2 0.14 0.83 6.5 6.46 0.54 4 0.35 2 7 6.95 0.38 2.8 0.56 3.2 7.5 7.39 0.22 1.6 0.77 4.4 8 7.82 0.11 0.81 0.90 5.2 MKH2PO4= 136.08 g / mol, MK2HPO4= 174.18 g / molpH values were adjusted with 1 M NaOH The KPi buffer at pH = 8 was prepared also with 1 M stock solutions. Therefore, 5.64 mL 1 M K2HPO4and 0.36 mL 1 M KH2PO4were mixed and filled up to 30 mL with deionized water and adjusted with 1 M NaOH. In the end, this buffer was used for the assay Table 3: Preparation of 200 mM BICINE in 30 mL for assay. pH at 30◦C pH at 25◦CBICINEm [g] n [mmol] 8 8.09 0.98 6 8.5 8.59 0.98 6 9 9.09 0.98 6 MBICINE= 163.17 g / mol pH values were adjusted with 1 M NaOH & 10 M NaOH. Table 4: Preparation of 200 mM CHES in 30 mL for assay. pH at 30◦C pH at 25◦CCHESm [g] n [mmol] 9 9.09 1.24 6 9.5 9.59 1.24 6 10 10.09 1.24 6 MCHES= 207.29 g / mol pH values were adjusted with 1 M & 10 M NaOH. Table 5: Preparation of 200 mM CAPS in 30 mL for assay. pH at 30◦C pH at 25◦CCAPSm [g] n [mmol] 10 10.05 1.33 6 10.5 10.55 1.33 6 11 11.05 1.33 6 MCAP S= 221.32 g / mol pH values were adjusted with 1 M NaOH & 10 M NaOH 5) Growth Media The LB medium was used for transformation purposes, making agar plates, inoculation of starter cultures and for expression main cultures. The ingredients of LB, TB, and autoinductionmedium are listed in the fol- lowing tables. Medium was autoclaved before further usage. Table 6: Recipe for LB medium for 400 mL. Component Quantity [g] NaCl 4 Bacteriological peptone 4 Yeast extract 2 For agar plates: 6 + Agar No. 1 → fill up to 400 mL dH2O → autoclave Table 7: Recipe for TB medium for 100 mL. Component Quantity [g] Tryptone 1.2 Yeast extract 2.4 Glycerol 0.5 K2HPO41.25 KH2PO40.23 → fill up to 100 mL dH2O; autoclave Table 8: Recipe for autoinduction medium for 1 L. Component Quantity [g] Tryptone 20 Yeast extract 5 Glycerol 6 Na2HPO46 KH2PO43 NaCl 5 Lactose 2 Glucose 0.5 → mix everything together and fill up to 1 L dH2O → autoclave 6) SDS-PAGE Commercial SDS-PAGE gels from BioRad were used. Depending on the needed amount of wells, 12 or 10% gels were used. 7) Preparation of Samples Crude E. coli cell suspension (or cell pellet that was resuspended in buffer) was normalized to OD600= 7 and mixed in a 1:1 ratio with SDS-PAGE 2x loading buffer (commercial). 10 µL of that mix was loaded on a SDS-PAGE gel. 8) Plasmid Isolation by Miniprep Plasmid DNA was isolated using the thermo scientific GeneJet plasmid miniprep kit or the NEB kit according tothe manufacturer’s instructions, eluting in 60◦C deionized water. The starter culture was prepared by takinga 50 mL conical plastic tube containing 10 mL autoclaved LB medium with an appropriate amount of antibi- otic, see table 13. The medium was inoculated with a single colony of E. coli containing the plasmid ofinterest. The tube was then placed in a shaker-incubator at 37◦C, 120 rpm, overnight. Cells were harvestedby centrifugation at 4800 RCF for 5 min at 4◦C9) BL21(DE3) Competent Cells Chemo competent cells (100 µL) were allowed to thaw on ice for 10 min before 5 µL DNA was added.The mixture was incubated on ice for 30 min, then a heat shock was performed at 42◦C for 15 s. After-wards, the mix was incubated on ice for another 5 min. Subsequently, 250 µL LB-medium was added.The cell culture was incubated for 1 h at 37◦C and 400 rpm on a table incubator. Afterwards, 250 µL ofthe cultivated cells were plated on LB-agar plate containing the appropriate antibiotic and the plates wereincubated over night at 30◦C.10) NEB 5-alpha competent cells Chemo competent cells (50 µL) were allowed to thaw on ice for 10 min before 5 µL of PCR product, treated with KLD mix, was added to it. The mixture was incubated on ice for 30 min, then a heat shockwas performed at 42◦C for 30 s. Afterwards, the mix was incubated on ice for another 5 min. Subse-quently, 950 µL SOC-medium was added. The cell culture was incubated for 1 h at 37◦C and 500 rpmin a table incubator. Afterwards, 100 µL were plated on a LB-agar plate containing the appropriate anti-biotic. The plates were incubated over night at 30◦C.11) C43 competent cells A C43 cell glycerol stock (provided by Dr. Isabel Oroz-Guinea) was used to prepare an overnight cul-ture (ONC) in 10 mL LB without antibiotic. The ONC was incubated at 37◦C, 120 rpm. On the nextday, 3 mL ONC was used to inoculate 300 mL LB in a 1 L baffled flask. The culture was incubated at30◦C, 120 rpm. After 2 h and 30 min, the OD600 reached 0.35. The flask was immediately placed onice for approximately 30 min. Meanwhile, the centrifuge bottles were cooled on ice. Afterwards, thesuspension was transferred into the bottles and centrifuged (4◦C, 15 min, 5000 rpm). The superna-tant was then discarded and the pellet resuspended in 30 mL of an ice cold 0.1 mM MgCl2 / CaCl2so-lution. Suspension was centrifuged (4◦C, 15 min, 4800 rpm), supernatant discarded and the pellet re-suspended in 20 mL of an ice cold 0.1 mM MgCl2 / CaCl2solution. The suspension was incubated onice for 25 min. Then, the resuspension was centrifuged again (4◦C, 15 min, 4800 rpm). The obtainedpellet was washed with 15 ml of an ice cold 85 mM CaCl2 / 15% glycerol solution. The suspension wascentrifuged a last time (4◦C, 15 min, 4800 rpm) and the pellet was then resuspended in 900 µL of anice cold 85 mM CaCl2 / 15% glycerol solution. The suspension was portioned as 100 µL in 1.5 mL plas-tic vials and shock frozen with liquid nitrogen. Shock frozen cells were stored at - 80◦C12) Transformation of BL21 (DE3) or Shuffle T7(DE3) Chemo competent cells (100 µL) were allowed to thaw on ice for 10 min before 5 µL DNA was added. Themixture was incubated on ice for 30 min, then a heat shock was performed at 42◦C for 15 s. Afterwards, the mixwas incubated on ice for another 5 min. Subsequently, 250 µL LB-medium was added. The cell culture was in-cubated for 1 h at 37◦C and 400 rpm on a table incubator. Afterwards, 250 µL of the cultivated cells were platedon LB-agar plate containing the appropriate antibiotic and the plates were incubated over night at 30◦C.13) Transformation of C43 (DE3) Chemo competent cells (100 µL) were allowed to thaw on ice for 10 min before 1 µL DNA was added. The mix-ture was incubated on ice for 30 min, then a heat shock was performed at 42◦C for 15 s. Afterwards, the mix wasincubated on ice for another 5 min. Subsequently, 900 µL LB-medium was added. The cell culture was incu-bated for 1 h at 37◦C and 700 rpm on a table incubator. Afterwards, 200 µL of the cultivated cells were plated onLB-agar plate containing the appropriate antibiotic and the plates were incubated over night at 30◦C14) Transformation of Ultra competent XL 10 gold cells To 50 µL of competent cells, 2 µL β-mercaptoethanol were added and the mix was allowed to thaw on ice for 10 min before 2 µL of PCR product was added to it. The mixture was incubated on ice for 30 min, then a heatshock was performed at 42◦C for 30 s. Afterwards, the mix was incubated on ice for another 2 min. Subsequently,500 µL LB-medium was added. The cell culture was incubated for 1 h at 37◦C and 400 rpm on a table incubator.Afterwards, everything was plated on a LB-agar plate containing the appropriate antibiotic. The plates were in-cubated over night at 37◦C15) Transformation of E. coli RosettaT M(DE3)Cells were thawed on ice for 10 min. After thawing, 100 µL of cells were moved into a 1.5 tube.2 µL of DNA was added for transformation and then incubated on ice for 30 min. The cells were heat shocked forexactly 30 sec at 42◦C in heat block. Afterwards, the tube was placed on ice for 5 min. 250 µL LB-me-dium warmed to 37◦C were added. Incubation at 30°C by shaking (500 rpm) for 1 h. 200 µL werespread onto a warm LB-KAN (25 µg / mL) or AMP (50 µg / mL) - CAM (34µg / mL) plate; incubate overnightat 30◦C.16) Bacterial strains E. coli BL21(DE3), Arctic, Shuffle T7, and C43 cells were used for expression. NEB 5-alpha and XL 10 gold cells were used to transform PCR product. 17) Storage of permanent cultures A 5 mL or 10mL pre-culture containing the appropriate antibiotic concentrations was inoculated with a singlecolony of E. coli strain containing plasmid of interest and incubated at 37◦C for 16 h. Aliquots of this culture were added to 60% sterile glycerol (30% final glycerol concentration) in plastic 1.5 mL vials and stored at -20◦C until further use.18) Heterologous Expression in E. coli In general, an overnight culture was prepared by inoculation of LB with a single colony containing the Geneof Interest (GOI) and the appropriate antibiotic. The cultivation was carried out at 30°C or 37◦C for 16h. Then, the cultivation of the main culture was done by inoculation of cultivation media with the over-night culture supplied with the specified antibiotic. The cultivation was continued at 30◦C or 37◦C until aspecific OD600was reached. The expression of the heterologous genes was then started by addition of the ap- propriate inducer and carried out for a specific duration, at given temperatures and shaking speed. Deviations from this standard protocol and specific requirements are listed in the following table. The associated plas- mid number for each of these enzymes is listed in that table as well. The usage of autoinduction medium demanded a slightly different protocol. The cultivation of bacteria was carried out by inoculation of cultiva-tion media supplied with the specified antibiotic with overnight culture. The cultivation continued at 37◦C for3 h. Afterwards, the temperature was changed to 20◦C. The expression is induced via lactose in the autoin-duction medium, which slowly activates the expression of the enzyme. Table 9a): Expression protocols of used enzymes. Entry Enzyme Expression strain Expression protocol (plasmid / ELKplasmid) 1 SpL E. coli BL21(DE3)TB, 37◦C, 120 rpm; OD6000.6-0.9 +(pRSFDuet-1 / none)0.25 mM IPTG, 20◦C, 120 rpmE. coli RoseT MO / N 2 CalBW104Dtta (DE3)(pET22b(+) / none)TB, 37◦C, 120 rpm; OD6000.5 +0.1 mM IPTG, 17◦C, 120 rpm O / NTable 9b) Expression strain +E. coli BL21(DE3) rpm; +(pRSFDuet-1 / pEG626)0.25 mM IPTG, 20◦C, 120 rpm O / NCalB WtE. coli RosettaT M(DE3) TB, 37◦C, 120 rpm; OD6000.5 +(pET22b(+) / none)0.1 mM IPTG, 17◦C, 120 rpm O / NMsAcT + variants E. coli BL21(DE3)LB, 30◦C, 120 rpm; OD6000.6-0.7 +(pET28a(+) / pEG357)0.5 mM IPTG, 20◦C, 120 rpm O / NCE13 + variants E. coli BL21(DE3)LB, 37◦C, 120 rpm; OD6000.6-0.7 +(pRSFDuet-1 / none)0.5 mM IPTG, 20◦C, 120 rpm O / NCE03 E. coli BL21(DE3)AutoTB, 120 rpm; first 30◦C for 4h,(pET26b(+) / none)then 20◦CCE07 E. coli BL21(DE3)AutoTB, 120 rpm; first 30◦C for 4h,(pET26b(+) / none)then 20◦CEstSm + variants E. coli BL21(DE3)LB, 37◦C, 120 rpm; OD6000.7-0.8 +(pET26b(+) / none) 0.1 mM IPTG + 100 mM CaCl2,20◦C, 120 rpm 11 hRML + variantsE. coli RosettaT M(DE3) LB, 37◦C, 120 rpm; OD6000.6-0.8 +(pET28a(+) / none)0.1 mM IPTG, 16◦C, 120 rpm O / NThe enzyme class of the used enzymes as well as the correlated antibiotic resistances are listed in Table 10. Table 10a): Used enzymes, according enzyme class and used antibiotic concentration. Entry Enzyme Enzyme class Antibiotic resistance 1SpL Lipasekan (50 µg mL−1)2CalBW104D Lipaseamp (50 µg mL−1)Table 10b) Entry Enzyme Enzyme class Antibiotic resistance 1SpL Lipasekan (50 µg · mL−1)2CalB Lipaseamp (50 µg · mL−1)3CE03 Esterasekan (50 µg · mL−1)4CE07 Esterasekan (50 µg · mL−1)5CE13 Esterasekan (50 µg · mL−1)6EstSm Lipasekan (50 µg · mL−1)7RML Lipasekan (50 µg · mL−1)8 MsAcT Acyltransferasekan (50 µg · mL−1)Table 11a): Hosts and their used antibiotic concentration. Entry Host Antibiotic resistance 1 BL21(DE3) none 2 NEB 5-alpha none 3RosettaT M(DE3) CAM (34 µg mL−1)Table 11b) Entry Host Antibiotic resistance 1 BL21(DE3) none 2 NEB 5-alpha none 3 Shuffle T7 (DE3) none 4 C43 (DE3) none 5 XL 10 gold cells none 6Arctic cells (DE3)GEN (20 µg · mL−1)*7RosettaT M(DE3) CAM (34 µg · mL−1)19) Cell Free Extract (CFE) After cell harvest, the cell pellet was resuspended 50 mM KPi buffer (pH 7.5) and centrifuged at 4800 x g at4◦C for 15 min. Afterwards, the supernatant was decanted and the cells were resuspended in 50 mM KPiat pH 7.5 buffer. The sonication was performed with a sonotrode connected to a wave generator. The cell suspension was repeatedly sonicated according to the protocol for the expressed enzyme (see Table 12).Insoluble cell residues were removed by centrifugation at 18,000 x g at 4◦C for 20 min.Table 12a): Sonication procedure for the used enzymes. Entry Enzyme Sonication procedure Repetitions 1 SpL 5 min, 1 s on / 2 s off, 40 % amplitude 1x 2 CalBW104D 4 min, 1 s on / 2 s off, 30 % amplitude 1x Table 12b) Entry Enzyme Sonication procedure Repetitions 1 SpL 5 min, 1 s on / 2 s off, 40 % amplitude 1x 2 CalB 4 min, 1 s on / 2 s off, 30 % amplitude 1x 3 CE03 4 min, 1 s on / 2 s off, 20 % amplitude 1x 4 CE07 4 min, 1 s on / 2 s off, 20 % amplitude 1x 5 CE13 4 min, 1 s on / 5 s off, 30 % amplitude 1x 6 EstSm 4 min, 1 s on / 2 s off, 30 % amplitude 1x 7 RML 4 min, 1 s on / 4 s off, 20 % amplitude 1x 8 MsAcT 4 min, 1 s on / 2 s off, 20 % amplitude 1x 20) Lyophilization of CFE Supernatant of sonicated cell pellet was transferred to a round bottomed flask and shock frozen with liquid nitrogen for several minutes. Afterwards, the frozen solution was attached to a lyophilizator and stayed there overnight. The round bottomed flask with the CFE was attached to the lyophilizator till a dry powder was ob- tained. 21) Biotransformation for pNPB or pNPA test For the reaction mixtures, 50 µL of 100 mg / mL CFE stock (10 mg / mL CFE) was mixed with 20 µL deion. water, 425 µL of 210 mM KPi buffer (pH 7.5), and 5 µL of 50 mM pNPB (stock in acetonitril) or 100 mM pNPA (stock in DMSO). The reaction took place at room temperature and the time was taken. As soon as the solution turned yellow, the time was stopped and noted. 22) Biotransformation for pH assay For the reaction mixtures, 25 mg of CFE was dissolved in 5 mL of 200 mM buffer. The reaction mixture was created with 870 µL of buffer for the ethyl 2-furoate reactions or 930 µL for the ethyl picolinate reactions. Afterwards, 10 µL of 1 M ethyl 2-furoate or ethyl picolinate stock solution in DMSO were added. Then, 20 µl of 1 M benzylamine stock solution in DMSO were added. These mixtures without the enzyme where then in-cubated for 5 minutes at 30◦C and 700 rpm. The enzyme solution was added, 100 µL for the reaction withethyl 2-furoate and 40 µL for the reaction with ethyl picolinate. The reaction mixture was incubated for 10minutes at 30◦C and 700 rpm. Afterwards, the reaction was quenched with 2 M HCl. The sample for theUHPLC measurement was prepared by combining 300 µL methanol with 300 µl of the reaction mixture. This was then centrifuged at 15,000 rpm for 15 min.200 µL of the supernatant liquid were used for the UHPLC measurement. For the empty cell reaction mixtures, 25 mg of cell free extract from E. coli without SpL were dissolved in 5 mL of 200 mM buffer. This was always done shortly before it was needed to avoid early deg- radation. The reaction mixture was created with 890 µL of buffer for ethyl 2-furoate and 950 µL for ethyl picolinate. To this, 10 µL of a 1 M ethyl 2-furoate or ethyl picolinate stock solution in DMSO were added. Thismixture without the CFE was incubated for 5 minutes at 30◦C and 700 rpm before adding the enzyme solution,100 µL for the mixture containing ethyl 2-furoate and 40 µL for the mixture containing ethyl picolinate. The reac-tion mixture was incubated for 10 minutes at 30◦C and 700 rpm. Afterwards, the reaction was quenchedwith 2 M HCl. The sample for the UHPLC measurement was prepared by combining 300 µL methanol with 300 µL of the reaction mixture. This was then centrifuged at 15,000 rpm for 15 min.200 µL of the supernatant liquid were used for the UHPLC measurement. 23) Biotransformation for aminolysis reaction – small scale substrate screening For the reaction mixtures, 20 mg of CFE (10 mg / mL CFE) was dissolved in 950 µL of 210 mM KPi buffer (pH 7.5). Afterwards, 10 µL deion. water and 20 µL of 1 M benzylamine DMSO stock (20 mM) were added. To start the reaction, 20 µL of 1 M ester DMSO stock (20 mM) were added. Final DMSO concentration was4%. These mixtures were then incubated at 30◦C and 700 rpm as long as needed. The sample for theHPLC measurement was prepared by combining 200 µL methanol with 200 µl of the reaction mixture. This was then centrifuged at 15,000 rpm for 15 min.200 µL of the supernatant liquid were used for the HPLC meas- urement. Table 13 Primers for fast cloning (SEQ ID NO:s 127-132). Melting temperature Tmwas calculated for the annealing bases (highlighted in red) with the Tmcalculator online tool from ThermoFisher Primer nameTm [◦C]Sequence (5’→ 3’)CE07_FC-Insert_for 65.3TGCCCAGCCGGCGATGGCCATGTCCTTGCAGGCCAGGCE07_FC-Insert_rev 60.6TCGAGTGCGGCCGCAAGCTTTGCCTCTTTAATGAACGCACE03_FC-Insert_for 68TGCCCAGCCGGCGATGGCCATGGCCTCAATCCCGGCACCE03_FC-Insert_rev 64.2TCGAGTGCGGCCGCAAGCTTGCTAGAAATTTCTGGGA-TAGTGGTG pET26b(+)_FC_for 72.5AAGCTTGCGGCCGCACTCGApET26b(+)_FC_rev 75.5GGCCATCGCCGGCTGGGCATable 14 PCR conditions and Thermocycling parameters Component Stock concentration Quantity added [µL] template c* 1 Forward primer 10 µmol 2.5 Reverse primer 10 µmol 2.5 Phusion buffer (HF) 5X 10 Phusion polymerase - 0.5 dNTPs 10 mM 1 DMSO 100% 2.5 Autoclaved water - 30 *DNA stock c in ng·µL−1: 50 (CE03), 50 (CE07), and 144 (pET26b(+)).Segment CyclesTemperature [◦C]Time [s]Initialisation 1 98 60 Denaturation 98 30Annealing 30 Ta30 Elongation 72 20 s / kb Final Elongation 1 72 300 Hold 1 4 ∞ Ta= 56 / 59 / 67 ◦C, CE07 / CE03 / pET26b(+).Tawas calculated with the ThermoFisher Tmcalculator online tool & its substraction with 5 gave the finalTa.After the PCR, 1 µL DpnI was added to 45 µL of PCR mix. Then, two different ratios were used to anneal vector and insert, namely 1:1 (1 µL pET26 + 1 µL insert (CE03 or 07)) or 1:5 (1 µL pET26 + 5 µL insert(CE03 or 07)). Both mixtures were digested at 37◦C for 1 h. Af- terwards, 2 µL were transformed into ultracomp. gold cells XL10 [see Example 14) Transformation of Ultra competent XL 10 gold cells]. Table 15 colony PCR conditions Component Stock concentration Quantity added [µL] Supernatant* - 10 PCR master mix (Dream Taq green) 2X 12.5 T7 Primer mix◊*A colony was picked & resuspended ◊stock was done by mixing 20 µmol of 100 µM for- & rev-primer with 60 µmol of H2O. Segment CyclesTemperature [◦C]Time [s]Initialisation 1 95 300 Denaturation 94 30Annealing 20 55 30 Elongation 72 120Final Elongation 1 72 600 Hold 1 4 ∞ 24) Mutagenesis of hydrolases The following primers were synthesized for the mutagenesis of the acyltransefrase from M. smegmatis and designed via the NEB tool ’NEBaseChanger’ on the website. Table 16 Primers (SEQ ID NOs: 133-162) for mutagenesis of hydrolases by Q5 Site-Directed Mutagen- esis Kit of NEB. Mutated position is highlighted in bold Entry Primer nameTm [◦C]Sequence (5’→ 3’)1 SpL_D158E_for 82 CCTGTCGGGCGAAAGCGCGGGCG 2 SpL_D158E_rev 78 ACCAGACCCGTGCAGGCAATATTGTCGGC 3 SpL_D158S_for 73 CCTGTCGGGCTCCAGCGCGGGCG 4 SpL_D158H_for 76 CCTGTCGGGCCATAGCGCGGGCG 5 SpL_D158Y_for 75 CCTGTCGGGCTATAGCGCGGGCG 6 SpL_D158N_for 76 CCTGTCGGGCAATAGCGCGGGCG 7 SpL_D158R_for 74 CCTGTCGGGCCGCAGCGCGGGCG 8 SpL_D158K_for 77 CCTGTCGGGCAAAAGCGCGGGCG 9 SpL_D158Q_for 77 CCTGTCGGGCCAGAGCGCGGGCG 10 SpL_D158T_for 68 CCTGTCGGGCACAAGCGCGGGCGG 11 SpL_D158T_rev 72 ACCAGACCCGTGCAGGCA 12 SpL_D158X_rev 72 ACCAGACCCGTGCAGGCAATATTG 13 CE13_E232D_for 66 TATTTTCGGGGATAGTGCGGGTG 14 CE13_E232D_rev 61 GTTACATTTGCAGGATCGC 15 MsAcT_D10A_for 64 GTGTTTTGGTGCTAGCCTGACCT 16 MsAcT_D10A_rev 61 AGAATACGTTTTGCCATATGG 17 MsAcT_D10I_for 58 GTGTTTTGGTATTAGCCTGACCTG 18 MsAcT_D10I_rev 57 AGAATACGTTTTGCCATC 19 RML_H143D_for 64 CGTGACTGGTGATAGTTTGGGTG 20 RML_H143D_rev 61 GCCACTTTGTAACTTGGG 21 EstSm_H205D_for 66 TATTAGTGGTGATAGCCTGGGCG 22 EstSm_H205D_rev 64 ACCACATCTTCGCCACTC 23 SpL_H102N CCTCGAAACGAACGATCCCTATTGC 24 SpL_H102N_rev TCGCCGATCACCCAGCCG 25 SpL_H102S CCTCGAAACGTCTGATCCCTATTGCGCCGAAGC 26 SpL_H102S_rev TCGCCGATCACCCAGCCG 27 SpL_H102Y CCTCGAAACGTATGATCCCTATTGCGC 28 SpL_H102Y_rev TCGCCGATCACCCAGCCG 29 SpL_H102V CCTCGAAACGGTCGATCCCTATTGCGCCG 30 SpL_H102V_rev TCGCCGATCACCCAGCCG X = E / S / H / Y / N / R / K / QFor the mutagenesis, the Q5®site-directed mutagenesis kit from NEB was used. The details of the mu-tagenesis are summarized in table 20 and 21. Step II from table 20 was incubated in general for 5 min. For SpL_D158Q, SpL_D158S, MsAcT_D10A, EstSm_H205D and RML_H143D the incubation time was extended for 1 h. After Step II, the mixture was incubated at room temperature for 15 min and afterwards transformed into NEB 5-alpha competent cells and plated on agar plate with the appropriate antibiotic. Table 17: PCR information on used template, annealing temperature and elongation time. Samplestock conc. [ng·µL−1] Annealing T [◦C]Elongation t [s]SpL_D158E 80 72 200 SpL_D158S 80 72 230 SpL_D158H 80 72 200 SpL_D158Y 80 72 200 SpL_D158N 80 72 200 SpL_D158R 80 72 200 SpL_D158K 80 72 200 SpL_D158Q 80 72 230 SpL_D158T 80 69 210 CE13_E232D 50 63 200 RML_H143D 100 62 210 EstSm_H205D 50 65 250 MsAcT_D10I 70 58 200 MsAcT_D10A 50 62 200 Table 18: PCR reaction components for the mutagenesis of the targets. Two steps were required. Step I - Exponential amplification Stock concentration Quantity added [µL] Component template see table 19 1 Forward primer 10 µmol 1.25 Reverse primer 10 µmol 1.25 Q5 Hot Start High-Fidelity Master Mix 2X 12.5 Autoclaved water 9Step II - KLD reactionComponent Stock concentration Quantity added [µL]PCR product from StepKLD reaction buffer KLD enzyme mix 10X 1 Autoclaved water 3Table 19: PCR thermocycling parameters for the mutagenesis. Segment CyclesTemperature [◦C]Time [s]Initialisation 1 98 30 Denaturation 98 10Annealing 30 see table 19 30 Elongation 72 see table 19 Final Elongation 1 72 120 Hold 10 ∞ 25) Results The inventors of the present invention have shown that a plurality of wildtype and mutated hydrolases are capable to be used for the present invention. An overview of the employed hydrolases and their activity in amide formation is given in Table 20. Table 20 summarizes of each enzyme the amino acid (AA) next to the catalytically active S, the catalytic triad, if amide formation was observed Enzyme AA -1 next to S Cat. triadAmide for-SEQ ID mationMsAcT wt D S / H / D ++ 88 MsAcT S11C D C / H / D - 90 MsAcT D10A A S / H / D + 92 MsAcT D10I I S / H / D + 94 MsAcT L12A / F154A D S / H / D ++ 96 MsAcT F154V / F174V D S / H / D ++ 98 MsAcT F174V D S / H / D ++ 100 MsAcT F154A / F174A D S / H / D + 102 MsAcT F150V / F154V D S / H / D ++ 104, 114 MsAcT F174A D S / H / D ++ 106 MsAcT F154V D S / H / D ++ 108 MsAcT F154L D S / H / D ++ 110 MsAcT F154A D S / H / D + 112 MsAcT F150V / F174V D S / H / D ++ No seq MsAcT F150A / F154A D S / H / D + 116 MsAcT F174A / F150A D S / H / D + 118 MsAcT T93A / F154A D S / H / D + 120 SpL wt D S / H / D +++ 2 SpL S159C D C / H / D + 4 SpL D158T T S / H / D + 6 SpL D158H H S / H / D - 8 SpL D158Y Y S / H / D - 10 SpL D158N N S / H / D + 14 SpL D158R R S / H / D - 16 SpL D158K K S / H / D - 18 SpL D158Q Q S / H / D - 20 SpL D158S S S / H / D ++ 22 SpL D158E E S / H / D +++ 24 SpL D158I I S / H / D - 26 CE13 wt E S / H / D - 28 CE13 E232D D S / H / D - 30 CE03 wt D S / H / D + 32 CE07 wt D S / H / D + 34 MAE2 wt G S / S / K - 36 CIH wt not known not known - 38 AMI wt not known not known - 40 PpATase F148V not known not known - 42 2R11 L S / H / E* - 44 CalB wt W S / H / D - 46 CalB QW10 V C / H / D + 52 CalB QW4 V S / H / D - 54 CalB W104D D S / H / D +++ 56 NfpolyA wt G S / S / K ++ 66 BsAmi wt G S / S / K + 78 PdAmi wt G S / S / K ++ 76 RmAmi wt G S / S / K + 84 RbAmi wt G S / S / K - 68 OctHD wt G S / S / K + 72 MsAmi wt G S / S / K + 80 Est2 wt D S / H / D ++ 126 PestE wt D S / H / D ++ 124 SpL H102S SpL H102N SpL H102V SpL H102Y Legend for amide (N-benzylfuran-2-carboxamide) formation: low (+ = 0-14%), medium (++ = 15-70%), very good (+++ = >70%).

Claims

Claims:

1. An isolated hydrolase capable of catalysing the reaction from an acyl donor to an amide in an aqueous me- dium comprising a hydrolase, an amine, an acyl donor, and optionally a solvent, wherein after incubation at least 10% of the acyl donor have been converted to an amide.

2. The isolated hydrolase of claim 1 wherein after incubation at least 20% of the acyl donor have been con- verted to an amide.

3. The isolated hydrolase of claim 1 or 2 comprising a sequence selected from the group consisting of f. The amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126, and g. An amino acid molecule having at least 50% identity to the amino acid molecule of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, or 126, or a functional fragment thereof, and h. An amino acid molecule encoded by a nucleic acid molecule of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and i. An amino acid molecule encoded by a nucleic acid molecule having at least 50% identity to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, and j. An amino acid molecule encoded by a nucleic acid molecule hybridizing under stringent conditions to a fragment of at least 250 bases complementary to SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 123, or 125 or a functional fragment thereof, wherein the amino acid molecule as defined in b., c., d. and e. is catalysing the reaction from an acyl do- nor to an amide in an aqueous medium.

4. The isolated hydrolase of claim 3, wherein the amino acid corresponding to position 102, 158, and / or 159 of SEQ ID NO: 2 is substituted by any other amino acid.

5. A process for producing an amide comprising the steps of iv. Providing an aqueous medium comprising a hydrolase, an amine, an acyl donor, and optionally a solvent,, v. Incubating the aqueous medium and vi. Optionally isolating the amide from the reaction mixture, wherein the one or more hydrolase is capable of catalysing the reaction from an acyl donor to an amide in an aqueous medium optionally comprising a solvent, a hydrolase and an acyl donor, wherein after in- cubation at least 10% of the acyl donor have been converted to an amide.

6. The process of claim 5 wherein after incubation at least 20% of the acyl donor have been converted to an amide.

7. The process of claim 5 or 6 wherein the hydrolase comprises a sequence as defined in claim 3 or 4.

8. A recombinant construct comprising a nucleic acid molecule encoding a hydrolase as defined in claim 3 or 4.

9. The recombinant construct of claim 8, wherein the hydrolase is functionally linked to a heterologous pro- moter.

10. A recombinant vector comprising the recombinant construct of claim 8 or 9.

11. A recombinant microorganism comprising the recombinant construct of claim 8 or 9 or the recombinant vector of claim 10.

12. The recombinant microorganism of claim 11 wherein the microorganism is Rhodococcus rhodochrous, Aerococcus sp., Ashbya gossypii, Aspergillus sp., Bacillus pumilus, Bacillus subtilis, Bacteroides thetai- otaomicron, Clostridium algidicarnis, Corynebacterium efficiens, Corynebacterium glutamicum, Esche- richia coli, Haloferax volcanii, Lactobacillus casei, Methanocaldococcus jannaschii, Methanothermobacter thermautotrophicus, Myceliophthora thermophila, Pichia pastoris, Pseudomonas synxantha, Pseudomo- nas azotoformans, Pseudomonas jluorescens, Pseudomonas ovalis, Pseudomonas stutzeri, Pseudomo- nas acidovolans, Pseudomonas mucidolens, Pseudomonas testosteroni, Pseudomonas aeruginosa, Pseudozyma tsukubaensis, Ralstonia eutropha, Rhodobacter sphaeroides, Rhodococcus opacus, Sac- charomyces cerevisiae, Shigella boydii, Sinorhizobium meliloti, Streptomyces antibioticus, Streptomyces avermitilis, Streptomyces cacaoi, Streptomyces coelicolor, Streptomyces flavelus, Streptomyces griseo- lus, Streptomyces lavendulae, Streptomyces lividans, Streptomyces olivaceus, Streptomyces ta- nashiensis, Streptomyces virginiae, Streptomyces viridochromogenes, Thermoplasma acidophilum, Vib- rio natrigens or Yarrowia lipolytica.

13. A composition comprising comprising a hydrolase comprising a sequence as defined in claim 3 or 4, an amine, an acyl donor, and optionally a solvent..

14. A recombinant microorganism comprising an introduced, increased or enhanced activity and / or expres- sion of one or more hydrolase comprising a sequence as defined in claim 3 or 4, wherein the one or more hydrolase is capable of catalysing the reaction from an acyl donor to an amide.

15. A method for fermentative production of an amide, comprising the steps of iii. Providing a recombinant microorganism of claim 14, iv. Culturing said microorganism in a medium comprising an acyl donor under conditions that allow for the production of said amide, and optionally isolating said amide from the medium.

16. A composition comprising one or more recombinant microorganisms according to claim 14.

17. A method for producing a recombinant microorganism of claim 14 comprising the steps of:introducing, increasing or enhancing the activity and / or expression of a hydrolase gene encoding a hy- drolase enzyme having an acyl donor converting activity in said microorganism.

18. The microorganism of claim 14 or the method of claim 17, wherein the microorganism is selected from Rhodococcus rhodochrous, Aerococcus sp., Ashbya gossypii, Aspergillus sp., Bacillus pumilus, Bacillus subtilis, Bacteroides thetaiotaomicron, Clostridium algidicarnis, Corynebacterium efficiens, Corynebacte- rium glutamicum, Escherichia coli, Haloferax volcanii, Lactobacillus casei, Methanocaldococcus jan- naschii, Methanothermobacter thermautotrophicus, Myceliophthora thermophila, Pichia pastoris, Pseudo- monas synxantha, Pseudomonas azotoformans, Pseudomonas jluorescens, Pseudomonas ovalis, Pseu- domonas stutzeri, Pseudomonas acidovolans, Pseudomonas mucidolens, Pseudomonas testosteroni, Pseudomonas aeruginosa, Pseudozyma tsukubaensis, Ralstonia eutropha, Rhodobacter sphaeroides, Rhodococcus opacus, Saccharomyces cerevisiae, Shigella boydii, Sinorhizobium meliloti, Streptomyces antibioticus, Streptomyces avermitilis, Streptomyces cacaoi, Streptomyces coelicolor, Streptomyces fla- velus, Streptomyces griseolus, Streptomyces lavendulae, Streptomyces lividans, Streptomyces oliva- ceus, Streptomyces tanashiensis, Streptomyces virginiae, Streptomyces viridochromogenes, Thermo- plasma acidophilum, Vibrio natrigens or Yarrowia lipolytica..

19. A recombinant expression construct comprising ii. a promoter functional in a microorganism functionally linked to a nucleic acid molecule encoding hydrolase, wherein the promoter functionally linked to the nucleic acid molecule encoding the hydrolase is heterolo- gous to the nucleic acid molecule encoding the hydrolase, and wherein the hydrolase comprises the sequence as defined in claim 3 or 4.

20. A recombinant vector comprising the recombinant expression construct of claim 19.

21. A recombinant microorganism comprising the recombinant expression construct of claim 19 or the re- combinant vector of claim 20.

22. A method of culturing or growing the recombinant microorganism of claim 14 or 21 comprising inoculating a culture medium with one or more of said recombinant microorganisms and culturing or growing said recombinant microorganism in culture medium comprising an acyl donor.

23. A use of a recombinant microorganism according to claim 14 or 21 or a composition according to claim 16 for the for the whole cell bio-conversion of an acyl donor to an amide.

24. A process for whole cell bio-conversion of an acyl donor to an amide comprising the steps of I) growing the recombinant microorganism according to claim 14 or 21 in a fermenter comprising an acyl donor, an amine, a medium suitable for growing said recombinant microorganism and II) recovering the amide thereof from the fermentation broth obtained in I).

25. A process for whole cell bio-conversion of an acyl donor to an amide comprising the steps of i) growing the recombinant microorganism according to claim 14 or 21 in a fermenter comprising a me- dium suitable for growing said recombinant microorganism, and ii) recovering the recombinant microorganism from the fermenter, andiii) performing a whole cell bio-conversion in an aqueous medium by supplementing an acyl donor, an amine and iv) recovering the amide from the aqueous medium obtained in iii).

Citation Information

Patent Citations

  • Compounds and methods for site directed mutations in eukaryotic cells

    US5565350A

  • RAC-like genes from maize and methods of use

    WO2000015815A1

  • Genomic sequence modification method for specifically converting nucleic acid bases of targeted DNA sequence, and molecular complex for use in same

    WO2015133554A1

  • Nucleobase editors and uses thereof

    WO2017070632A2